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Doxorubicin (DOX) is an anthracycline antibiotic that has cytotoxic actions.  The 
therapeutic use of DOX to treat a wide array of cancers is limited by a dose-dependent 
cardiotoxicity.  Although DOX is known to have several adverse side-effects, acute and 
chronic cardiotoxicity have received the most attention as both may eventually lead to 
heart failure.  While exercise has been shown to protect against DOX cardiotoxicity, a 
clear and consistent mechanism to explain its cardioprotective effects is lacking.  High 
performance liquid chromatography (HPLC) is a valuable instrument that can be used to 
evaluate cardiac DOX accumulation.  We hypothesized that a reduction in cardiac DOX 
accumulation may be a mechanism of exercise-induced cardioprotection.  Therefore, the 
purpose of this study was to determine if exercise preconditioning reduces cardiac DOX 
accumulation, thereby providing a possible mechanism to explain the cardioprotective 
effects of exercise against DOX toxicity.  Female Sprague-Dawley rats were randomly 
assigned to 1 of 3 primary experimental groups: sedentary (SED), voluntary wheel 
running (WR) or treadmill (TM).  Animals in WR and TM groups completed 10 weeks of 
exercise prior to DOX treatment.  DOX was administered 24 hours after the last training 
session as a bolus i.p. injection at 10 mg/kg.  Subgroups of rats from each primary group 
were sacrificed at 1, 3, 5, 7, and 9 days post exposure and cardiac function was analyzed.  
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Twenty-four hours following sacrifice, cardiac DOX accumulation was analyzed using 
HPLC.  DOX treatment resulted in both in vivo and ex vivo cardiac dysfunction.  
However, 10 weeks of either involuntary or voluntary exercise preconditioning preserved 
cardiac function.  Additionally, significant differences were observed between sedentary 
and exercise groups for DOX accumulation.  The greatest accumulation of DOX was 
observed in SED+DOX 1 day post injection.  When compared to SED+DOX (day 1), 
DOX accumulation in TM+DOX (day 1) and WR+DOX (day 1) groups was significantly 
reduced (p < 0.05).  Similarly, DOX accumulation in SED+DOX at both 3 and 5 days 
was significantly greater than both TM+DOX and WR+DOX at 3 and 5 days, 
respectively (p < 0.05).  DOX accumulation in TM+DOX and WR+DOX groups was 
non-existent at both 7 and 9 days.  Because DOX accumulation remained elevated in 
SED+DOX at 7 days, it was significantly greater than TM+DOX and WR+DOX groups 
(p < 0.05).  Therefore, it is possible that the cardioprotective effects of exercise against 
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Epidemiological research over the last decade suggests that cancer incidence and 
death rates for all cancers combined are decreasing mainly as a result of advances in early 
detection and improved therapeutic strategies (National Cancer Institute, 2009).  
Chemotherapy is commonly used for the treatment of disease via chemicals that either 
have a specific toxic effect upon disease-producing microorganisms or selectively destroy 
cancer cells.  The most common chemotherapeutic anthracycline used clinically is 
doxorubicin (DOX; trade name Adriamycin).  In 1974, clinicians started prescribing 
DOX to cancer patients as a chemotherapy treatment (Minotti, Menna, Salvatorelli, 
Cairo, & Gianni, 2004; Weiss, 1992).  While the antineoplastic activity of DOX is 
evident, the exact mechanisms are unknown.  It is hypothesized that DOX causes 
deoxyribonucleic acid (DNA) biosynthesis inhibition (Gewirtz, 1999), apoptosis 
(Clementi, Giardina, Di Stasio, Mordente, & Misiti, 2003), and free radical-mediated 
cellular injury (Minotti, Menna, et al., 2004).  Despite its effective antineoplastic 
properties, the administration of DOX is limited as a result of its relatively high rate of 
dose-dependent cardiotoxicity (Jain, 2000). 
DOX-induced cardiotoxicity is characterized by acute cardiac injury that may 
progress to irreversible cardiomyopathy and congestive heart failure months to years 
following treatment (Singal & Iliskovic, 1998; Singal, Li, Kumar, Danelisen, & Iliskovic, 
2000).  The exact mechanisms of DOX mediated cardiotoxicity are unknown; however, 
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oxidative stress appears to be the largest contributor.  The C-ring of DOX undergoes 
heavy redox cycling in cardiomyocytes.  The DOX quinone moiety oxidizes nicotinamide 
adenine dinucleotide dehydrogenase oxidoreductase (NADH) to form a semiquinone.  In 
an attempt to reform the quinone, oxygen (O2) is immediately reduced and reactive 
oxygen species (ROS) such as superoxide anion (O2 .-) and hydrogen peroxide (H2O2) are 
formed (Minotti, Menna, et al., 2004). 
Several studies suggest that chronic exercise training prior to DOX treatment 
attenuates DOX-induced cardiotoxicity (Chicco, Schneider, & Hayward, 2005, 2006; 
Hydock, Lien, Schneider, & Hayward, 2008; Wonders, Hydock, Greufe, Schneider, & 
Hayward, 2009).  Additionally, recent research indicates that acute and short-term 
exercise is cardioprotective against DOX-mediated cardiac dysfunction (Jensen, et al., 
2009; Jensen, Hydock, Lien, Schneider, & Hayward, 2008; Lien, Hydock, Jensen, 
Schneider, & Hayward, 2009; Wonders, Hydock, Schneider, & Hayward, 2008).  The 
mechanisms associated with exercise-induced cardioprotection against DOX 
cardiotoxicity are not fully understood.  However, exercise may protect cardiac tissue 
from DOX-induced dysfunction by increasing antioxidative enzyme activity and 
expression (Ascensao, Magalhaes, Soares, et al., 2005; Chicco, Hydock, Schneider, & 
Hayward, 2006), decreasing lipid peroxidation (Ascensao, Magalhaes, et al., 2005a; 
Ascensao, Magalhaes, et al., 2005b; Chicco, Schneider, et al., 2006; Wonders, et al., 
2009), upregulating heat shock protein 72 (HSP72) (Chicco, et al., 2005), preserving  
myosin heavy chain (MHC) isoform distribution (Hydock, Lien, Jensen, et al., 2009; 
Hydock, et al., 2008; Jensen, et al., 2009; Lien, et al., 2009), or downregulating 
proapoptotic enzymes (Wonders, et al., 2009).  Additionally, a recent pilot study by our 
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laboratory using high performance liquid chromatography (HPLC) has shown that less 
DOX accumulates in cardiac tissue of exercised rats when compared to sedentary rats 
(Bradshaw, Karnilaw, Hayward, & Hyslop, 2009).  Thus the cardioprotective effects of 
exercise may be due, at least in part, to a difference in the accumulation of DOX in the 
heart.   
Since both short-term and chronic exercise preconditioning are cardioprotective in 
rats receiving DOX, it is hypothesized that DOX accumulation would be reduced in 
exercise preconditioned rats when compared to their sedentary counterparts.  One 
possible explanation for a reduction in DOX accumulation could be an increased 
expression of multidrug resistance associated proteins (MRPs).  Cancer cells express 
MRPs, which are glycoproteins capable of antitumor agent translocation (Krause, et al., 
2007).  DOX that is introduced to cancerous cells can initiate apoptosis or necrosis; 
however, when MRPs are expressed, DOX is extruded from the cell thereby preventing 
its accumulation inside the cell.  The result is a decrease in DOX accumulation and an 
increased likelihood of tumor proliferation.  If MRPs are upregulated in cardiomyocytes 
of exercised animals, these cardiac cells may accumulate less DOX (Krause, et al., 2007) 
thereby providing a theoretical basis for exercise-induced cardioprotection against DOX 
toxicity. 
Statement of Purpose 
 The purpose of this study was two-fold: (a) to investigate the effects of chronic 
exercise preconditioning on cardiac DOX accumulation and to what extent it is related to 
DOX induced cardiac dysfunction, and (b) to apply an HPLC based method for a time-
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course determination of DOX clearance in a complex biological sample matrix (rat left 
ventricular tissue). 
Research Hypotheses 
H1 Detectable quantities of DOX from left ventricular tissue will decrease as 
time elapses following DOX exposure. 
H2 Chronic exercise trained animals will have less DOX accumulation in left 
ventricular tissue when compared to sedentary animals throughout a 9-day 
observation period. 
H3 Chronic exercise before DOX treatment will preserve cardiac function, 
and this will be related to a decline in DOX accumulation in the hearts of 
exercised animals. 
Need for the Study 
 Cancer survivorship has improved in recent decades, however, toxicity associated 
with some of the most effective chemotherapeutic antibiotics still exists.  One of the most 
widely used antineoplastic agents is DOX (Jain, 2000).  DOX is used in the treatment of 
several cancers, however, it is associated with a dose-dependent cardiotoxicity that can 
eventually progress to heart failure (Singal & Iliskovic, 1998).  Doxorubicin 
cardiotoxicity is characterized by acute cardiac injury that may progress to irreversible 
cardiomyopathy and congestive heart failure months to years following treatment 
(Ferrans, Clark, Zhang, Yu, & Herman, 1997).  However, exercise training can offer 
protection against a variety of acute and chronic myocardial injuries (Ascensao, 
Magalhaes, Soares, Ferreira, Neuparth, Appell, et al., 2005).  It has been shown that 
exercise preconditions the myocardium so that it is protected against oxidative stress by 
increasing antioxidative enzyme activity and expression, increasing heat shock protein 
content, preserving MHC, and possibly reducing the accumulation of DOX in 
cardiomyocytes.  Less DOX accumulation in rat myocardia may reduce the various forms 
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of injury to cardiac tissue, and this adaptation may protect the hearts of preconditioned 
rats against cardiac dysfunction and injury induced by DOX treatment.  Currently, there 
are no studies that have examined the effectiveness of exercise training on cardiac DOX 
accumulation.  Therefore, this investigation is focused on the use of exercise to attenuate 





ABC - ATP binding cassette  
LVDPd - LVDP during diastole 
AFC - affinity chromatography  
LVDs - LV end systolic diameter 
AIF - apoptosis-inducing factor 
LVEDV - LV end diastolic volume 
ATP - adenosine triphosphate  
LVESV - LV end systolic volume  
Ca++ - calcium 
MDR - multidrug resistance proteins 
CAT - catalase 
MHC - myosin heavy chain 
CO - cardiac output 
MPT - membrane permeability transition 
DNA - deoxyribonucleic acid 
MPTP - membrane permeability transitional pore 
DAUN - daunorubicin 
MRPs - multidrug resistance associated proteins 
DOX - doxorubicin 
mtDNA - mitochondrial DNA 
DOX-ol - doxorubicinol  NADH - nicotinamide adenine dinucleotide dehydrogenase 
oxidoreductase 
dP/dtmax - maximum rate of developed pressure NO - nitric oxide 
dP/dtmin - minimum rate of developed pressure ONOO- - peroxynitrite  
EDP - end diastolic pressure 
O2 - oxygen  
EPI - epirubicin 
O2 
.- - superoxide anion 
EPIDAUN - epidaunorubicin 
·OH - hydroxyl radical 
ESP - end systolic pressure 
PWd - posterior wall thickness during diastole 
ET - ejection time of aortic blood flow 
PWs - posterior wall thickness during systole 
ERK - extracellular signal-regulated kinases ROS - reactive oxygen species 
Fe2+/Fe3+ - iron  
RONS - reactive oxygen and nitrogen species 
FS - fractional shortening 
RPLC - reversed phase liquid chromatography  
GPx - glutathione peroxidase 
RWT - relative wall thickness 
HPLC - high performance liquid chromatography 
SEC - size exclusion chromatography  
HR - heart rate 
SED - sedentary 
HSPs - heat shock proteins 
SOD - superoxide dismutase 
HSP70 - heat shock protein 70  
SV - stroke volume 
HSP72 - heat shock protein 72  
SWd - septal wall thickness during diastole 
H2O2 - hydrogen peroxide SWs - septal wall thickness during systole 
IDA - idarubicin 
TM - treadmill  
IEC - ion exchange chromatography 
A-Vmax - maximal aortic flow velocity 
i.p. - intraperitoneal 
A-Vmean - mean aortic flow velocity 
i.v. - intravenous  
M-Vmax - maximal mitral flow velocity  
LV - left ventricle 
M-Vmean - mean mitral flow velocity 
LVDd - LV end diastolic diameter 
VTI - velocity time integral  
LVDP - LV developed pressure 
WR - voluntary wheel running 
LVDs - LV end systlic diameter 
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Delimitation of the Study 
Samples in this study included 10-11 week old female Sprague-Dawley rats (180-
210 g).  Cardiotoxicity was induced using a 10 mg/kg bolus intraperitoneal (i.p.) injection 
of DOX.  The exercise training groups ran on a motorized treadmill at 30 m/min up an 
18% grade for 60 minutes, 5 days a week for 10 weeks. 
Definition of Terms 
Apoptosis - programmed cell death. 
Cardiolipin - obligatory phospholipids localized to the inner mitochondrial 
membrane, responsible for maintenance of the structure and metabolic function of the 
mitochondria membrane proteins. 
Cardioprotection - adaptations in the heart that provide increased tolerance to 
ischemic or chemical induced injury. 
DOX-induced cardiotoxicity - development of cardiac abnormalities following the 
exposure to DOX. 
Echocardiogram - an ultrasonic technique used to image real-time cardiac tissue 
dimensions and blood flow velocities. 
High performance liquid chromatography - a form of column chromatography 
used frequently in biochemistry and analytical chemistry to separate, identify and 
quantify compounds.  HPLC can utilize a column that holds chromatographic packing 
material, a pump that moves the mobile phase through the column, and a detector that 
shows the retention times of molecules such as DOX. 
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MHC - an abundant contractile protein.  The ATPase associated with each MHC 
hydrolyzes ATP.  In cardiomyocytes, there are two MHC isoforms (α and β).  The α-
MHC has faster ATPase activity in comparison to β-MHC. 
M-mode - An imagining mode used to determine cardiac geometry during 
echocardiography.  
Multidrug resistant proteins - proteins found in cellular membranes responsible 
for the efflux of xenobiotics. 
Membrane permeable transitional pores - protein pore formed in the 
mitochondrial membrane under stress induced conditions.  When induced, it contributes 
to mitochondrial swelling, dysfunction, and cellular apoptosis. 
Mitochondrial dysfunction - the impairment of function or abnormalities observed 
exclusively in the mitochondria.  The dysfunction is primarily due to the adverse effects 
of drugs, infections, or other environmental causes. 
Necrosis - the premature death of living cells and tissue. 










REVIEW OF LITERATURE 
Introduction 
Anthracyclines are a specific group of antineoplastic drugs known to have the 
widest range of clinical use of any class of drugs in oncology (Minotti, Menna, et al., 
2004).  The anthracyclines are highly effective anticancer antibiotics used in the 
treatment of a variety of malignancies.  Of the anthracyclines, DOX, is the most effective 
and has the greatest range of treatment, however, its use is limited clinically by a dose-
dependent cardiotoxicity which may eventually lead to heart failure (Lipshultz, et al., 
2005; Singal, et al., 2000).  The acute form of cardiotoxicity often develops within a short 
period of time following DOX treatment (Ferrans, et al., 1997; Tokarska-Schlattner, 
Zaugg, Zuppinger, Wallimann, & Schlattner, 2006).  Numerous molecular mechanisms 
for DOX cardiotoxicity have been hypothesized (Minotti, Menna, et al., 2004; Zucchi & 
Danesi, 2003), however, oxidative stress (Krause, et al., 2007; Schimmel, Richel, van den 
Brink, & Guchelaar, 2004), mitochondrial dysfunction (Zhou, Starkov, Froberg, Leino, & 
Wallace, 2001) and apoptosis  (Minotti, Menna, et al., 2004) appear to be the largest 
contributors. 
Results from animal studies indicate that chronic exercise training (Chicco, 
Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et al., 2006; Hydock, et al., 
2008; Wonders, et al., 2009) and short-term exercise (Jensen, et al., 2009; Jensen, et al., 
2008; Wonders, et al., 2008) can attenuate DOX-mediated cardiotoxicity.  DOX 
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treatment leads to impairment in both in vivo (Hydock, Lien, & Hayward, 2009; Hydock, 
et al., 2008) and ex vivo (Hydock, Wonders, Schneider, & Hayward, 2009; Wonders, et 
al., 2009) cardiac function.  It has been demonstrated that exercise protects against DOX-
induced cardiac dysfunction by preserving end systolic pressure (ESP), end diastolic 
pressure (EDP), left ventricular developed pressure (LVDP), maximum rate of developed 
pressure (dP/dtmax), and minimum rate of developed pressure (dP/dtmin) (Hydock, et al., 
2008; Jensen, et al., 2008; Wonders, et al., 2009; Wonders, et al., 2008).  The 
mechanisms by which exercise offers protection from myocardial injury are not fully 
understood; however, an increase in antioxidative capacity (Ascensao, Magalhaes, 
Soares, et al., 2005; Chicco, Hydock, et al., 2006) appears to play an important role. 
In order to directly study cardioprotective cellular mechanisms, many instruments 
and techniques have been used.  One such method is chromatography, a physical 
separation of components in a mixture of compounds (Loadman & Calabrese, 2001; 
Wang, Mallette, & Parcher, 2008).  Bradshaw et al. (2009) assert that HPLC is useful for 
quantifying DOX accumulation in experiments with sedentary and exercise 
preconditioned rats.   
The purpose of this study was to investigate the effects of chronic exercise 
preconditioning on cardiac DOX accumulation and its relationship to DOX-induced 
cardiac dysfunction.  An additional purpose of this investigation was to apply an HPLC-
based method for a time-course determination of DOX accumulation in a complex 





 Daunorubicin (DAUN) and DOX are among the most effective and commonly 
prescribed antineoplastic chemotherapeutic agents (Weiss, 1992).  In 1963, researchers’ 
derived DAUN from Streptomyces peucetius.  Shortly after its discovery, DAUN was 
used clinically to treat myeloblastic leukemias (Weiss, 1992).  Over a decade later, DOX, 
a 14-hydroxy analog of DAUN, was clinically prescribed to cancer patients in the United 
States for the treatment of childhood tumors, lymphomas, and breast cancer (Minotti, 
Menna, et al., 2004).  To date, there are over 2000 antrhacycline analogs; however 
DAUN, DOX, epirubicin (EPI), and idarubicin (IDA) are the most clinically relevant.   
Despite the common use of DOX, the antineoplastic mechanisms are not fully 
understood.  The primary antitumor mechanism of DOX is hypothesized to involve DNA 
intercalation.  DOX inhibits DNA biosynthesis by migrating into cells via simple 
diffusion and binding to proteosomes in the cytoplasm, thereby forming a DOX-
proteasome complex that can cross the nuclear membrane.  Upon dissociation of the 
proteasome, DOX binds to DNA.  Consequently, DOX stimulates double-stranded DNA 
scission and inhibits topoisomerase activity which prevents DNA replication in the cell 
(Cummings, Anderson, Willmott, & Smyth, 1991; Gewirtz, 1999; Lothstein, et al., 2000).  
Furthermore, the antineoplastic effects of DOX may in part be attributed to cytotoxic free 
radicals induced by DOX (Minotti, Menna, et al., 2004).  Free radicals are responsible for 
events leading to lipid peroxidation, DNA damage and apoptosis; however, their role is 





The utilization of DOX is limited due to acute and chronic cardiotoxicity.  DOX 
cardiotoxicity is characterized by acute cardiac injury that may progress to irreversible 
cardiomyopathy and congestive heart failure months to years following treatment (Singal 
& Iliskovic, 1998; Singal, et al., 2000).  The acute form of cardiotoxicity often develops 
within minutes, hours, or days following DOX treatment (Ferrans, et al., 1997; Tokarska-
Schlattner, et al., 2006).  Cardiac arrhythmias, pericarditis, hypotension, myofibrillar 
disorganization, cardiomyocyte vacuolization, and elevated serum enzyme markers are 
all signs of acute cardiotoxicity (Abdel-Wahab, et al., 2003; Ferrans, et al., 1997; Lefrak, 
Pitha, Rosenheim, & Gottlieb, 1973; Mihm, Yu, Weinstein, Reiser, & Bauer, 2002; 
Parry, et al., 2009; Schimmel, et al., 2004; Singal & Iliskovic, 1998).  Even though the 
early signs of cardiac dysfunction are reversible, acute toxicities associated with DOX are 
highly predictive of chronic toxicities (Cardinale, et al., 2002; Nousiainen, Jantunen, 
Vanninen, & Hartikainen, 2002). 
Chronic DOX cardiotoxicity may present months, years, or decades after DOX 
has been cleared from the body.  DOX cardiotoxicity is responsible for structural changes 
of the myocardia which may lead to functional changes.  Decreased cardiac function due 
to DOX cardiotoxicity (indicated by a reduction in left ventricular ejection fraction) 
(Ferrans, et al., 1997), is often caused by dilated cardiomyopathy (Singal & Iliskovic, 
1998), which may eventually lead to congestive heart failure and dysrhythmias years 
following exposure to DOX (Steinherz, Steinherz, Tan, Heller, & Murphy, 1991).  
Approximately 5% of patients who receive a 550 mg/m2 commutative dose of DOX will 
develop dilated cardiomyopathy within 4-20 years (Steinherz, et al., 1991).  This 
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percentage increases when higher doses are administered (Singal, Iliskovic, Li, & Kumar, 
1997). 
Mechanisms of Doxorubicin Cardiotoxicity 
Oxidative Stress 
The exact mechanisms of DOX mediated cardiotoxicity are unknown; however, 
oxidative stress appears to be the largest contributor.  The production of excessive 
quantities of reactive oxygen and nitrogen species (RONS) is an important mechanism of 
DOX-induced cardiotoxicity.  The C-ring of DOX undergoes redox cycling in 
cardiomyocytes.  The DOX quinone moiety oxidizes NADH to form a semiquinone.  In 
an attempt to reform the quinone, O2 is immediately reduced and ROS such as O2.- and 
H2O2 are formed (Minotti, Menna, et al., 2004).  O2.- is a potent free radical that can 
injure cardiomyocytes.  In the presence of the antioxidant enzyme, superoxide dismutase 
(SOD), O2.- can undergo dismutation in which O2.- is converted to hydrogen peroxide 
H2O2.  If O2.-  is not converted to H2O2, it may combine with nitric oxide (NO) to form 
peroxynitrite (ONOO-), a powerful nitrogen oxygen species known to affect key proteins 
in myocardial tissue (McCord, 1985).  Glutathione peroxidase (GPx) or catalase (CAT), 
two antioxidant enzymes located in cardiomyocytes, can convert H2O2 into water.  
However, if H2O2 is not converted to water, it may react with iron (Fe²+/Fe³+) to form a 
hydroxyl radical (·OH), which is known to be the most potent free radical produced and 
has a greater cellular toxicity than O2·- (Muindi, Sinha, Gianni, & Myers, 1984).  





Mitochondria play a key role in cardiac cell survival and death.  They are 
essential for adenosine triphosphate (ATP) production, regulation of intracellular calcium 
(Ca++) homeostasis, and the main generators of intracellular ROS (Zhou, et al., 2001).  
Damage to the mitochondrial membranes may result in the excessive production of ROS, 
formation and dysfunction of membrane permeability transitional pores (MPTP), and a 
release of apoptotic proteins.  Therefore, mitochondria control many of the pathways that 
lead to cellular death (Crompton, 1999; Singal, et al., 2000). 
DOX exhibits a strong affinity for cardiolipin, an abundant and obligatory lipid 
that is localized to the inner mitochondrial membrane (Cheneval, Muller, Toni, Ruetz, & 
Carafoli, 1985; Goormaghtigh, Huart, Praet, Brasseur, & Ruysschaert, 1990; Yaroslavov, 
et al., 2003).  Cardiolipin when combined with DOX causes cytochrome c to be released, 
decreasing both ATP production and inducing apoptosis.  A recent report suggested that 
DOX is capable of migrating beyond the membrane and penetrating the mitochondrial 
matrix to directly interact with mitochondrial DNA (Ashley & Poulton, 2009b).  This in 
part, may explain the cardioselective mitochondrial toxicity of DOX.  Additionally, the 
large quantity of mitochondria in cardiomyocytes (approximately 30-35% of the total cell 
volume), the cardiomyocyte demand of a continuous supply of ATP for contractile 
purposes, and the abundance of ATP derived from oxidative metabolism all contribute to 
the mitochondrial specificity of DOX and the deleterious effects on mitochondrial 
bioenergetics (Carvalho, et al., 2010; Herman & Young, 1979; Tokarska-Schlattner, et 
al., 2006). 
15 
Several other mitochondrial structures and processes provide primary targets for 
drug-induced toxicity and cell death (Starkov & Wallace, 2002).  Lemasters and 
colleagues (1998) reported that drug-induced oxidative injury caused pyridine nucleotide 
oxidation, mitochondrial generation of RONS, and increased mitochondrial Ca++ 
concentrations, leading to an induction of MPTP.  The theory behind MPTP induction is 
that cytoxicity stimulates mitochondrial permeability transition (MPT).  MPT is a 
phenomenon whereby the controlled permeability of the inner mitochondrial membrane is 
altered and the mitochondria are no longer selectively permeable to solutes such as Ca++; 
thus leading to depolarization of the membrane and osmotic swelling (Crompton, 1999; 
Kroemer & Reed, 2000; Lemasters, et al., 1998).  It is hypothesized that the disruption of 
the mitochondrial membrane due to the unnecessary depolarization of the membrane may 
lead to the release of cytochrome c and other apoptogenic factors in the intermembrane 
space, such as apoptosis-inducing factor (AIF), endonuclease G, and procaspase-9 
(Crompton, 1999; Gillick & Crompton, 2008; Kroemer & Reed, 2000). 
Mitochondrial dysfunction induced by MPT is linked to DOX cardiotoxicity.  
MPT is a direct consequence of mitochondrial Ca++ overload, known to cause the 
inhibition of ATP synthesis and the release of apoptotic factors (Gillick & Crompton, 
2008; Lemasters, et al., 1998).  Calcium enters the mitochondria electrophoretically and 
is controlled by a transport cycle driven by the proton pumps of the respiratory chain.  
Under physiological conditions mitochondrial Ca++ controls key metabolic regulatory 
enzymes such as pyruvate dehydrogenase, oxoglutarate dehydrogenase, and isocitrate 
dehydrogenase in the mitochondrial matrix.  However, under conditions associated with 
ATP depletion and oxidative stress, mitochondrial Ca++ stimulates the opening of MPTP, 
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allowing more Ca++ to enter the matrix and inducing Ca++ overload which is known to be 
an important factor in cellular injury (Crompton, 1999; Gillick & Crompton, 2008). 
In DOX treated rats, the stimulation of mitochondrial calcium cycling is marked 
by an increased sensitivity of cardiac mitochondria to calcium-induced membrane 
depolarization (Sokolove & Shinaberry, 1988).  The significance of increased sensitivity 
to calcium is that the mitochondrial response to changing calcium concentrations is 
compromised (Solem, Heller, & Wallace, 1996; Solem, Henry, & Wallace, 1994).  Thus, 
induction of MPTP by DOX results in an energy-consuming cyclical uptake and release 
of calcium across the inner membrane, depolarization, reduced ATP, and eventually, cell 
death.  Mitochondrial dysfunction may also be the result of DOX’s ability to intercalate 
mitochondrial DNA (mtDNA).  Recently, Ashley et al., (2009a) reported that DOX and 
other DNA intercalators, intercalated mtDNA within living cells and caused mtDNA 
depletion.  Therefore, DOX-mediated mitochondrial dysfunction does not appear to be 
limited to oxidative stress (Ascensao, Magalhaes, Soares, et al., 2005), calcium 
homeostasis (Solem, et al., 1994), or MPT induction (Crompton, 1999). 
Exercise-Induced Cardioprotection 
The benefits of chronic exercise training are well established.  Endurance training 
can improve cardiac function (Vella & Robergs, 2008) and is known to play an essential 
role  in the management of heart failure (Papathanasiou, Tsamis, Georgiadou, & 
Adamopoulos, 2008), hypertension (Hansen, Nielsen, Saltin, & Hellsten, 2010), 
hyperlipidemia (Wang, Hu, et al., 2009), hypercholesterolemia (Blake & Triplett, 1995), 
and atherosclerosis (Kadoglou, Iliadis, & Liapis, 2008).  Other physiological adaptations 
that occur with endurance exercise include increased stroke volume (SV), decreased 
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resting heart rate (HR), and increased cardiac output (CO) which contributes to overall 
improved cardiac function (Wilmore, et al., 2001).  Exercise is also recognized for its role 
in cardioprotection.  Studies have been conducted using both chronic exercise training 
(Chicco, Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et al., 2006; 
French, et al., 2008; Hydock, et al., 2008; Quindry, et al., 2005; Wonders, et al., 2009) 
and short-term exercise (Demirel, et al., 2001; French, et al., 2008; Hamilton, et al., 2001; 
Wonders, et al., 2008) to limit the cardiac injury associated with ischemia and various 
pharmacological agents.  Several cellular mechanisms have been attributed to the 
cardioprotective effects of exercise training.  Many studies have reported that DOX-
mediated acute cardiotoxicity can be attenuated by an increase in myocardial antioxidant 
capacity, HSP72 expression, α-MHC isoform, and DOX extrusion. 
Increased Antioxidant Capacity 
If RONS are not managed by myocardial antioxidants, enhanced production of 
RONS results in several destructive processes in cardiomyocytes.  Overexpression of a 
free radical scavenger protein, metallothionein, is known to play a significant role in the 
reduction of DOX-induced cardiotoxicity in transgenic mice (Kang, Chen, Yu, Voss-
McCowan, & Epstein, 1997; Naganuma, Satoh, & Imura, 1988; Satoh, Naganuma, & 
Imura, 1988).  Antioxidant enzymes such as SOD, CAT, and GPx are important proteins 
found in cardiomyocytes, and when overexpressed in transgenic mice, the deleterious 
effects of DOX are attenuated (Gouaze, et al., 2001; Kang, Chen, & Epstein, 1996; Yen, 
Oberley, Vichitbandha, Ho, & St Clair, 1996).  Additionally, it has been hypothesized 
that increases in myocardial antioxidant capacity can be induced by exercise, contributing 
to cardioprotection during periods of elevated oxidative stress (Ascensao, Magalhaes, 
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Soares, et al., 2005; Atalay & Sen, 1999).  Numerous studies have reported that exercise 
increases the overall antioxidant capacity and it appears that increases in content (Siu, 
Bryner, Martyn, & Alway, 2004) and/or activity (Chicco, et al., 2005; Gunduz, Senturk, 
Kuru, Aktekin, & Aktekin, 2004; Husain, 2002, 2003; Husain & Somani, 1997; Kanter, 
Hamlin, Unverferth, Davis, & Merola, 1985; Powers, et al., 1998) of SOD, CAT and GPx 
in cardiac tissue are responsible for this adaptation.   
In contrast to the aforementioned studies, a significant increase in myocardial 
SOD, CAT, and/or GPx activities are not a requisite for exercise-induced 
cardioprotection.  Some studies have reported inconsistencies in the antioxidant adaptive 
response to exercise (Atalay & Sen, 1999; Ji & Mitchell, 1994; Rinaldi, et al., 2006).  Ji 
and Mitchell (1994) reported that neither myocardial GPx nor CAT activities were altered 
by exercise.  Jensen et al., (2008) reported no statistical increase or preservation of SOD 
and CAT activities in short-term preconditioned rats that received a 10 mg/kg bolus i.p. 
injection of DOX, however, cardioprotection was still observed.  Therefore, the role that 
exercise plays in the regulation of the antioxidant system is complex in nature and 
currently not fully understood. 
Myocardial Heat Shock  
Protein Expression 
Heat shock proteins (HSPs) are known to play a key role in attenuating oxidative 
injury in cardiomyocytes (Hamilton, et al., 2003; Starnes & Taylor, 2007).  In models of 
ischemia-reperfusion injury (Murlasits, Lee, & Powers, 2007; Quindry, et al., 2007) and 
acute DOX cardiotoxicity (Chicco, et al., 2005; Chicco, Schneider, et al., 2006), exercise 
induced an upregulation of HSP and offered cardioprotection in rats.  HSPs are believed 
to have protective effects by reducing oxidative injury, preventing the denaturing of key 
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regulatory proteins, and reducing apoptosis and necrosis (Ascensao, Magalhaes, et al., 
2006; Powers, Quindry, & Hamilton, 2004).  Animals that trained on a treadmill 5 
days/wk up a 6% grade at 20 m/min for 60 min expressed a 12.3-fold increase in 
myocardial HSP70 when compared to sedentary rats (Harris & Starnes, 2001).  Similarly, 
Chicco et al. (2005) reported that 8 weeks of voluntary wheel running led to an 
upregulation of cardiac HSP72 expression and prevented cardiac dysfunction induced in 
rats by the perfusion of 10 µM of DOX for 60 minutes.  In another study by Chicco et al. 
(2006), results suggested that DOX-induced cardiac dysfunction was attenuated by 
increased cardiac expression of HSP72 in rats chronically trained for 12 weeks, when 
compared to the SED+DOX animals.  Furthermore, Murlasits et al. (2007) reported that 
short-term exercise upregulated HSP72 and offered cardioprotection.  Despite evidence 
that suggests exercise induced HSP upregulation reduces cardiac injury, other reports 
suggested cardioprotection is not necessarily due to an increase in myocardial HSP 
expression (Starnes, Choilawala, Taylor, Nelson, & Delp, 2005), especially with short-
term exercise (Hamilton, et al., 2001; Jensen, et al., 2009; Taylor, Harris, & Starnes, 
1999). 
Myosin Heavy Chain  
Isoform Distribution 
 MHC isoform distribution is known to influence cardiac function, and the 
shifting of MHC isoforms can be significantly affected by DOX treatment (Hydock, et 
al., 2008; Hydock, Wonders, et al., 2009).  It was reported that 5 days post DOX 
treatment, sedentary animals displayed a significant increase in the percentage of β-MHC 
isoform, which contains the slower ATPase of the two isoforms.  Exercise 
preconditioning, however, attenuates this isoform shift (Hydock, et al., 2008).  
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Additionally, rats that performed voluntary wheel running exercise while receiving DOX 
expressed significantly higher levels of α-MHC isoform, the faster ATPase isoform, 
when compared to their sedentary counterparts (Hydock, Wonders, et al., 2009).  
Although a preservation of the MHC isoform distribution may not completely explain the 
protective effects of exercise, it may be one of several adaptations that contribute to its 
cardioprotective effects.   
Doxorubicin Accumulation 
Following the administration of anthracyclines such as DOX and EPI, 
accumulation in cardiac tissue can occur very quickly (Buja, Ferrans, Mayer, Roberts, & 
Henderson, 1973; Salvatorelli, Menna, Lusini, Covino, & Minotti, 2009; Urva, Shin, 
Yang, & Balthasar, 2009).  Timour et al. (1988) reported that intracellular concentrations 
of DOX (4,000 ng/g) in canine myocardial cells, far exceeded plasma concentrations 3 
hours after administration.  Additionally, it was reported, following a 1.5 mg/kg 
intravenous (i.v.) infusion of DOX, no detectable concentration was observed in plasma, 
however, 200 ng/g was still detected in the myocardial tissue 1 week post-infusion.  Little 
is known regarding the accumulation of DOX in rat cardiac tissue.  Recently, many 
methods have been developed to quantify DOX in plasma, serum, and tissues (Ahmed, et 
al., 2009; Maudens, Stove, Cocquyt, Denys, & Lambert, 2009; Urva, et al., 2009).  
However, none of the reported methods have validated their findings with cardiac 
function.  Based on the proposed mechanisms of DOX cardiotoxicity, it may be possible 
that a reduction in cardiac DOX accumulation could result in a reduced state of oxidative 
stress, mtDNA interference, mitochondrial dysfunction and apoptosis.  Furthermore, a 
recent pilot study by our laboratory using HPLC has shown that less DOX accumulates in 
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cardiac tissue of exercised rats when compared to sedentary controls (Bradshaw, et al., 
2009).  Thus a cardioprotective effect of exercise may be the result of a difference in the 
accumulation of DOX in the cardiac tissue of exercise trained rats. 
Multidrug Resistance Proteins 
A reduction in DOX accumulation may be the result of increased expression of 
MRPs.  MRPs are glycoproteins embedded in the cellular membrane which are 
responsible for pumping xenobiotics out of the cell (Krause, et al., 2007; Patel, Dunn, & 
Sorokin, 2002).  These proteins belong to a superfamily of proteins known as ATP 
binding cassette (ABC) transporters (Sorokin, 2004).  Depending on location and tissue 
type, MRPs can be further categorized into subgroups including: MRP-1, MRP-2, MRP-
3, MRP-4, MRP-5, MRP-6 and MRP-7.  Studies have reported the expression of MRP-1, 
MRP-2 (Rosati, et al., 2003)  and MRP-5 (Dazert, et al., 2003; Meissner, et al., 2007) in 
cardiac tissue.  Additionally, the MRP-1/GS-X pumps have received attention due to their 
potential role in DOX extrusion (Krause, et al., 2007).  A theory was proposed by Krause 
et al. (2007) which considered the possibility that DOX may be extruded via MRP-1/GS-
X pumps known to be expressed in cell membranes (de Bittencourt Junior, Curi, & 
Williams, 1998) and suggested less DOX would reside in cardiomyocytes if MRP-1/GS-
X pumps were upregulated in cardiac cells.  Furthermore, Krause et al. (2007) reported 
rats that performed 60 minutes of swimming exercise for 1 week expressed a 2.4-fold 
increase in myocardial MRP-1, when compared to their sedentary counter-parts; 
however, DOX accumulation was not determined.  Therefore, if MRPs are upregulated in 
cardiomyocytes of exercised animals, cardiac cells may accumulate less DOX thereby 
providing a theoretical basis for exercise-induced cardioprotection against DOX toxicity. 
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High Performance  
Liquid Chromatography 
One purpose of this study was to determine the accumulation of DOX in rat 
cardiac tissue as time elapses following DOX exposure using HPLC.  Chromatography is 
a method of physically separating the components in a mixture of compounds.  This 
technique provides information about the compounds general structures (polar 
characteristics) (Korecka & Shaw, 2009; Zacharis, 2009).  Specifically, liquid 
chromatography can separate liquid samples by passing the sample over a solid 
(stationary phase) with constant polarity.  The stationary phase is composed of hydrated 
silica gel (hydrocarbons).  The hydrocarbons are polar and adhere to a steel column.  A 
liquid sample, when introduced to a liquid solvent, may be dissolved (mobile phase).  
The mobile phase is responsible for wicking (wetting) the stationary phase.  As the 
solvent wicks the stationary phase, it interacts with the sample.  The solvent dissolves the 
sample due to the intermolecular attractions between the sample and the solvent.  The 
sample will also be attracted to the stationary phase.  As the sample is dissolved in the 
solvent, it moves down the column in a “zigzag path” (i.e. dissolved in the solvent, 
absorbed on the stationary phase, dissolved in the solvent, absorbed on the stationary 
phase, and so on).  Different compounds will have different attractions for the solvent and 
for the stationary phase, thus they will move down the stationary phase at different rates.  
It is in this process that separation occurs.  The effectiveness of separating a complex 
sample mixture depends on the “zigzag” frequency (Gooding & Regnier, 2002).  
The extent of sample separation is proportional to the total surface area, therefore, 
if the stationary phase has a greater surface area, the components of a mixture have more 
opportunity to interact with the stationary phase.  In HPLC, the stationary phase is ground 
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to a fine powder (to increase surface area) and particles are packed tightly together in a 
steel column making it more difficult for the solvent to elute through the column.  The 
flow rate is increased by using high pressures to force the solvent through the column 
(Schiel, Joseph, & Hage, 2010).  Both increased surface area and high pressure allows for 
a more efficient separation of compounds, hence the name high performance liquid 
chromatography (Korecka & Shaw, 2009).  HPLC is a highly precise technique capable 
of separating out different compounds that possess even the slightest differences.  
Therefore, HPLC may be used to identify the concentration of various compounds in 
biological samples (e.g., concentration levels of DOX in cardiac tissue).  
Several extensive reviews regarding the investigation of anthracyclines with the 
use of HPLC have been published (Chen, Thoen, & Uckun, 2001; Loadman & Calabrese, 
2001; Tjaden & de Bruijn, 1990).  However; the analysis, isolation, and purification of 
biomolecules can be accomplished by a number of different chromatographic modes 
(DiFrancesco, Griggs, Donnelly, & DiCenzo, 2007; Dodde, et al., 2003; Kummerle, et 
al., 2003; Li & Huang, 2004; Wall, McMahon, Crown, Clynes, & O'Connor, 2007).  Each 
method is based on interactions between the sample biomolecules and the packing 
material of the column.  The various methods of liquid chromatography are based on 
separations due to the biomolecule’s charge, size, and hydrophobicity during elution 
through porous packing material.  Therefore, it is important to identify the inherent 
differences between the modalities used for quantification purposes.  The primary 
methods used for quantification of biological samples, including methods specific to 
DOX, will be reviewed in this section.   
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Size Exclusion Chromatography 
The most commonly used modes are size exclusion chromatography, ion 
exchange chromatography, affinity chromatography, and adsorption chromatography.  
Size exclusion chromatography (SEC) is a versatile chromatographic method in which 
components of a biological sample are separated according to their molecular size with 
respect to the porous packing material (Barth, Boyes, & Jackson, 1994; Yao & Lenhoff, 
2004).  Larger molecules elute from the column first due to their inability to penetrate the 
pores of the packing material (Yao & Lenhoff, 2004), while some smaller molecules can 
enter into the packing particles thus delaying their elution (Barth, et al., 1994; Stadalius, 
Ghrist, & Snyder, 1987).  SEC is an uncomplicated method for separating biomolecules, 
because it is not necessary to keep the composition of the mobile phase constant during 
elution (Barth, et al., 1994; Stulik, Pacakova, & Ticha, 2003).  However, in comparison 
to other methods such as reversed-phase chromatography, this method is limited by its 
capacity for separation of biomolecules (Neue, 2008; Stulik, et al., 2003). 
Affinity Chromatography  
Affinity chromatography (AFC) is based on the properties of a molecule’s ability 
to specifically bind to a ligand (Schiel & Hage, 2009).  AFC is commonly used in basic 
science research and pharmaceutical drug development for the purification of chemicals 
or biomolecules using specific interactions between biological pairings (e.g., enzyme and 
enzyme substrate) via ligand binding (Ohtsu, et al., 2005).  Ligands are used in the 
column packing material to adsorb specific biomolecules.  Upon ligand binding, a 
conformational change occurs and the elution of the biomolecule is altered.  In 
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comparison to other methods, AFC is an efficient and very selective technique used for 
separation of large volumes of biomolecules (Neue, 2008; Schiel & Hage, 2009). 
Ion Exchange Chromatography 
The basis for ion exchange chromatography (IEC) is simple; charged 
biomolecules will bind to oppositely charged molecules in column packing materials 
(Jungbauer & Hahn, 2009).  Proteins have charged molecules on their surfaces, which 
change with the pH of the solution (Jungbauer & Hahn, 2009; Yigzaw, Hinckley, Hewig, 
& Vedantham, 2009).  Biomolecules with a greater charge bind more strongly to the 
packing material regardless of pH, however, weaker charges are easily influenced by 
slight changes in pH.  IEC is a very selective separation technique and has a high binding 
capacity that can be used on a wide variety of proteins over a short period of time 
(Jungbauer & Hahn, 2009; Langford, Xu, Yao, Maloney, & Lenhoff, 2007) .  
Reversed Phase Chromatography  
Reversed phase liquid chromatography (RPLC) is a specific type of adsorption 
chromatography that allows for separation based on hydrophobic interactions between the 
biomolecule and the ligand on the chromatographic column (Roses, Subirats, & Bosch, 
2009; Wang, Tian, Bi, & Row, 2009).  Typically, the RPLC’s stationary phase contains a 
large volume of hydrophobic ligands, while the mobile phase additives, such as acetic 
acid, increase protein hydrophobicity by forming ion pairs that strongly adsorb to the 
stationary phase (Nikitas & Pappa-Louisi, 2009; Wang, Tian, et al., 2009).  The main use 
for RPLC is for the separation peptides, however, less frequently, it can also be used to 
separate proteins (Li & Huang, 2004; Neue, 2008; Wang, et al., 2008).  The main draw to 
RPLC is that the method is the most efficient of all the biopolymer separation techniques 
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(Sandra, et al., 2008).  RPLC is particularly effective for separating chemical compounds 
in biological samples, which makes RPLC the most coveted mode for the determination 
of anthracyclines, such as DOX,  in plasma, serum, and tissues (Dodde, et al., 2003; 
Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009; Wall, et al., 2007).  
High Performance Liquid Chromatography  
and Doxorubicin 
Several reverse phase methods for determination of anthracyclines in plasma, 
serum, or tissues have recently been published (Ahmed, et al., 2009; Maudens, et al., 
2009; Salvatorelli, et al., 2009; Urva, et al., 2009).  The most recent recommended 
methods for anthracycline analysis are summarized in Table 2.  Urva et al. (2009) 
reported a less labor intensive method that was successfully used to quantify DOX 
accumulation in plasma and cardiac samples following administration of an i.v. bolus 
dose at 10 mg/kg in Swiss–Webster mice.  A Zorbax 300SB C18 (250 mm × 4.6 mm, 
5 µm) column was used for separation.  The mobile phase was comprised of 25% 
acetonitrile and 75% water in the presence of 0.1% triethylamine (pH 3).  A constant 
flow rate of 1.2 mL/min was used for the separation.  Plasma and tissue sample treatment 
involved a single protein precipitation step with perchloric acid.  DOX and DAUN 
retention times were reported to be 5.9 and 13.1 minutes, respectively.  The limit of 
detection for doxorubicin in the heart tissue was: 1.54 ng/mL.  The method was validated 
for precision and accuracy over a concentration range of 5-1000 ng/mL and DOX 
accumulation was measured up to 3 days post DOX exposure.  A significant decline in 
DOX accumulation in measured parameters reduced quickly over a 12 hour period.  
However, DOX was still detected in cardiac tissue 72 hours post treatment.  The 
aforementioned study’s methodology is most comparable to the method used in the study 
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by Bradshaw et al. (2009) to quantify DOX in rat cardiac tissue.  Bradshaw et al. (2009) 
reported an HPLC method that successfully determined the accumulation of DOX in LV 
tissue of sedentary and exercise trained rats.  Similarly, other methods have reported the 
use of HPLC in the determination of anthracyclines (Ahmed, et al., 2009; Arnold, Slack, 
& Straubinger, 2004; DiFrancesco, et al., 2007; Gilbert, McGeary, Filippich, Norris, & 
Charles, 2005; Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009).  
Specifically, DOX can be determined in various biological matrices (i.e. plasma, serum, 
effluent, and tissues) using reverse phase HPLC (Kummerle, et al., 2003; Urva, et al., 
2009).  EPI (Li & Huang, 2004), and doxorubicinol (DOX-ol) (Ahmed, et al., 2009; 
Arnold, et al., 2004; DiFrancesco, et al., 2007; Gilbert, et al., 2005), a secondary alcohol 
metabolite of DOX, were also quantified using various HPLC methods.  Methods 
specifics can vary based on the internal standards used for accumulation comparison, 
sample preparation, column type, and detection.  In the following section, various 






















































































































































































































































































































































































































































































































































































































































































































An internal standard is a known concentration of a known compound.  It differs 
from an analyte, in which the concentration of the compound is unknown.  Typically, the 
signal from an analyte is compared to the internal standard’s signal in order to calculate 
the concentration of the analyte.  DAUN is the most commonly used internal standard for 
the quantification of DOX (DiFrancesco, et al., 2007; Kummerle, et al., 2003; Urva, et 
al., 2009).  However, with success, epidaunorubicin (EPIDAUN) was reportedly used as 
an internal standard  (Li & Huang, 2004).  In a study by Bradshaw et al. (2009), DAUN 
was used as an internal standard for the quantification of DOX accumulation in rat 
cardiac tissue and eluted approximately 2 minutes after the elution of DOX.  
Sample Preparation  
In order for a biological sample to be analyzed using HPLC, it must first be 
prepared for separation.  With samples containing DOX, a purification step must be 
completed.  The most commonly used processes include deproteinization (Ahmed, et al., 
2009; Arnold, et al., 2004; Kummerle, et al., 2003; Urva, et al., 2009), liquid-liquid 
extraction (Maudens, et al., 2009), solid phase extraction (DiFrancesco, et al., 2007; Li & 
Huang, 2004), and back extraction (Loadman & Calabrese, 2001).  Deproteinization (a 
process of protein removal from a substance) occurs with the use of acids and it is an 
essential step in the HPLC analysis of DOX.  Acids used for deproteinization in previous 
studies included perchloric acid, trichloroacetic acid and picric acid for protein 
precipitation (Ahmed, et al., 2009; Bradshaw, et al., 2009; Kummerle, et al., 2003; Urva, 
et al., 2009).  Solid phase extraction (process by which compounds are dissolved or 
suspended in a liquid) was successfully used to purify samples for the analysis of both 
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DOX (DiFrancesco, et al., 2007) and EPI (Li & Huang, 2004).  A very time intensive 
technique was used by Gilbert et al. (2005) to purify plasma samples from parrots in 
which deproteinization was followed by a liquid–liquid extraction and then a back-
extraction (a sequential extraction of organic material) for the analysis of DOX and 
DOX-ol accumulation.  Based on the reports from the studies mentioned afore, it may be 
concluded that the purification of DOX, in biological samples, is not limited to technique.  
Separation Column and Detection  
The specificity of HPLC analyses depends largely on the separation column and 
the detection method.  For adequate separation and elution, the column must incorporate 
the analyte molecule size.  Many studies have used C-18 columns (18-carbon chain 
packing material) (Arnold, et al., 2004; Bradshaw, et al., 2009; DiFrancesco, et al., 2007; 
Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009) and reported high accuracy 
and precision when quantifying DOX, however, only two studies reported the use of a 
less hydrophobic column, C-8 phenylhexyl (column containing a shorter carbon chain 
packing material) (Ahmed, et al., 2009; Gilbert, et al., 2005) to quantify DOX.  Results 
from these studies suggest that DOX, due to its size, may be more easily eluted through a 
C-18 column with greater separation than a C-8 column.  Following the elution of DOX 
through the column, it must be detected.  Fluorescence (Bradshaw, et al., 2009; Gilbert, et 
al., 2005; Kummerle, et al., 2003; Urva, et al., 2009), chemiluminescence (Ahmed, et al., 
2009), and tandem-mass spectrometry (Arnold, et al., 2004; DiFrancesco, et al., 2007; Li 
& Huang, 2004) are the most commonly used methods in the detection of DOX in 
biological samples.  Thus, the detection of DOX is not limited to one type of detector; 
however, some reports suggest that tandem-mass spectrometry may have a greater 
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specificity over fluorescence detectors (Freisleben, Schieberle, & Rychlik, 2003; Sai, 
Kaniwa, Ozawa, & Sawada, 2002).   
Summary 
DOX is an anthracycline antibiotic that has cytotoxic actions.  The therapeutic use 
of DOX to treat a wide array of cancers is limited by a dose-dependent cardiotoxicity.  
DOX is known to have several adverse side-effects, however, acute and chronic 
cardiotoxicity have received the most attention as both may eventually lead to heart 
failure.  It is well accepted that cardiotoxicity of DOX is associated with generation of 
oxidative stress and an interference with mitochondrial function.  While exercise has 
been shown to be cardioprotective against DOX cardiotoxicity, a clear and consistent 
mechanism to explain its cardioprotective effects is lacking.  HPLC is a valuable 
instrument that can be used to evaluate cardiac DOX accumulation.  It was hypothesized 
that exercise will reduce the accumulation of DOX in cardiac tissue, which may 
contribute to the preservation of cardiac function and protect the heart against the acute 
injury induced by DOX treatment.  Therefore, it is possible that the cardioprotective 
effect of chronic exercise preconditioning may be due to a reduction of DOX 














 The purpose of this study was to determine the effects of chronic exercise 
preconditioning on DOX accumulation and cardiac function.  This was achieved by 
training rats using two different exercise protocols prior to DOX exposure (Figure 1).  
DOX was administered 24 hours after the last training session as a bolus i.p. injection in 
doses that are known to result in acute cardiac injury.  The cumulative dose of DOX was 
10 mg/kg.  Control animals received a bolus i.p. injection of 0.9% saline.  Rats were 
sacrificed 1, 3, 5, 7, and 9 days post exposure and cardiac function was analyzed.  One 
day following sacrifice, DOX accumulation was analyzed via HPLC.  
Subjects 
Female Sprague-Dawley rats (10-11 week old, 190-210 g) were housed two per 
cage in a temperature-controlled facility with a 12:12-hr light-dark cycle.  Rats were 
provided standard rat chow and water ad libitum.  All protocols used for the study were 
approved by the University of Northern Colorado Institutional Animal Care and Use 
Committee (IACUC) and are in compliance with the Animal Welfare Act guidelines.  All 
rats were randomly assigned to sedentary (SED), treadmill (TM), or wheel running (WR) 
exercise groups. 
 
Figure 1.  Exercise Timeline and Experimental Design.  Each open horizontal rectangle   
( ) represents 1 week of involuntary treadmill running exercise.  Each closed 
horizontal rectangle     (
Open arrows (ò) represent sacrifice times.  SED = sedentary
exercise; WR = 10 weeks of wheel running exercise; SAL = saline injection; DOX = 
doxorubicin injection. 
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Wheel running distances were monitored using Vital View data acquisition systems 
(MiniMitter, Bend, OR). 
Table 3  
Chronic exercise treadmill training protocol. 
Drug Treatment 
After the completion of the sedentary or activity period, all animals remained 
sedentary 24 hours prior to treatment with DOX.  Following the 24 hour sedentary 
period, each animal was randomly assigned to one of four experimental groups as 
illustrated in Figure 1: SED+SAL, SED+DOX, TM+DOX, WR+DOX.  Animals 
undergoing saline treatment received a 1.0 mL i.p. bolus injection of 0.9% saline.  
Animals treated with DOX received a 10 mg/kg bolus injection of DOX (Bedford Labs, 
Bedford, OH).  Subgroups of rats from each primary group were sacrificed at 1, 3, 5, 7, 
and 9 days following injections.   
Cardiac Function 
Left ventricle (LV) function was assessed in vivo and ex vivo.  In vivo cardiac 
function was assessed using transthoracic echocardiography on sedated rats with a 
commercially available echocardiographic system (Toshiba Nemio 30; 10 MHz 
transducer).  Animals were sedated with ketamine (40 mg/kg, i.p.) and echocardiography 
was completed within 10-15 minutes after the administration of the sedative.  Animals 
were placed in the left lateral decubitus position and the probe was positioned to obtain 
short-axis, long-axis, and four-chamber views.  From the short-axis view, an M-mode 
Variable  Week 
 1 2 3 4 5 6 7 8 9 10 
Speed (m/min) 13 21 26 30 30 30 30 30 30 30 
Grade (%) 5 10 15 18 18 18 18 18 18 18 
Duration (min) 20 30 30 60 60 60 60 60 60 60 
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tracing of the LV was obtained for measures of septal wall thickness during systole 
(SWs) and diastole (SWd), posterior wall thickness during systole (PWs) and diastole 
(PWd), LV end systolic diameter (LVDs), and LV end diastolic diameter (LVDd).   
Aortic flow was assessed from the five-chamber apical view using pulsed wave 
Doppler, with the smallest possible sample volume placed at the level of the aortic 
annulus.  Using a four-chamber apical view, mitral flow was assessed using pulsed wave 
Doppler with the smallest possible sample volume placed at the tips of the mitral valve.  
LV mass was calculated as 1.04[(LVDd + PWd + SWd)3 – LVDd3], and fractional 
shortening (FS) was calculated as (LVDd – LVDs)/LVDd.   
From pulsed Doppler mitral and aortic flow images, the velocity time integral 
(VTI), maximal flow velocity (Vmax), mean flow velocity (Vmean), acceleration time (AT), 
and deceleration time (DT) were measured.  Measures of filling time (FT) and ejection 
time (ET) were obtained from mitral and aortic Doppler flow images, respectively.  For 
all measures, data from three consecutive cardiac cycles, when possible, was obtained 
and averaged.   
Ex vivo cardiac function was analyzed using an isolated working heart model 
(ADInstruments, Colorado Springs, CO).  This analysis was conducted immediately 
following echocardiography procedures.  After each animal received an i.p. injection of 
heparinized (100U) sodium pentobarbital (50 mg/kg), the heart was quickly excised.  The 
aorta was cannulated and the heart was subjected to retrograde perfusion using Krebs 
buffer (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 
17 mM glucose, and 0.5 mM EDTA) until the coronary vasculature was cleared of blood.  
The pulmonary vein was cannulated and flow was re-directed to enter the left atrium.  
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Preload was set at 10 cm H2O and afterload set at 100 cm H2O above the cannula.  A 
microtip catheter pressure transducer (Scisense, Ontario, Canada) was inserted into the 
LV cavity via the apex for measurement of LVDP, maximal rate of pressure development 
(dP/dtmax) and the maximal rate of pressure decline (dP/dtmin).  Hearts were paced at 240 
beats/min using electrodes attached to the cannulae, and LV performance data were 
collected using a PowerLab/8e data acquisition system (ADInstruments, Colorado 
Springs, CO) following a 5 minute equilibration period.  LVDP was calculated by 
subtracting left ventricular ESP from EDP. 
Biochemical Analysis 
High Performance Liquid  
Chromatography 
Left Ventricular Tissue Preparation.  Immediately after the perfusion period, 
hearts were trimmed free of surrounding connective tissue and fat, blotted dry, and 
weighed.  The LV was then isolated, flash frozen in liquid nitrogen, and stored at –80°C 
for 24 hours.  Tissue samples were then subjected to a drug extraction procedure taken 
from previously validated methods (Alvarez-Cedron, Sayalero, & Lanao, 1999; 
Bradshaw, et al., 2009).  Approximately fifty milligrams of LV tissue was diluted with a 
0.067 M phosphate buffer (pH 7.4) and homogenized at 8000 RPM for 20 seconds using 
a Virtishear homogenizer (Virtis, Gardner, NJ).  The concentration of heart tissue was 
approximately 25 mg/mL.  Homogenates were then subjected to protein precipitation by 
adding 200 µL of a 50:50 (v/v) mixture of HPLC grade methanol and 40% ZnSO4 to 150 
µL of homogenized heart tissue.  Fifty microliters of DAUN (Sigma, St. Louis, MO) at an 
initial concentration of 500 ng/mL was added to the sample as an internal standard.  The 
sample was vigorously vortexed for one minute before centrifugation at 1500g for 10 
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minutes.  The supernatant fluid was filtered through a 0.2 micron syringe filter and 
injected directly onto the column to initiate the analytical method. 
Analytical Method 
The HPLC system consisted of two LC-10AT LC pumps for high-pressure 
gradient elution (Shimadzu Co., Japan).  A reverse-phase Zorbax Rx-C8 4.6mm x 15 cm 
column (Agilent Technologies, Santa Clara, CA) was used for separation and operated at 
40°C.  The following mobile phase (solvent) line configuration was held for all analyzes: 
solvent line A - HPLC-grade water, solvent line B - HPLC-grade acetonitrile, solvent line 
C - phosphate buffer, and solvent line D - HPLC-grade methanol.  At the end of each 
day’s HPLC analyses, solvent line C was purged of phosphate buffer and stored in water 
and solvent line B was purged of acetonitrile and stored in HPLC-grade methanol. 
The initial phase conditioned the system in the following manner: 65:35 (v/v) 
methanol/water at 0.1 mL/min flow rate through the column over-night and through the 
next morning by the conditioning method displayed in Table 4.  Figure 2 illustrates the 













HPLC mobile phase composition and pump parameters used for the system conditioning 
program (conditioning method).  The pump mobile phase program configuration was:  
solvent line A - HPLC-grade water, solvent line B - HPLC-grade water, solvent line C - 
HPLC-grade methanol, and solvent line D - HPLC-grade methanol.  The initial mobile 
phase composition was 65:35 (v/v) methanol (from solvent line D)/water (from solvent 
line A) at a 0.1mL/min flow rate.  Conc. = concentration of designated solvent.  
Time Module Action Value 
0.01 Pumps Total Pump A Flow 1.00 mL/min 
30.00 Pumps Solvent D Conc. 100.0% 
180.00 Pumps Solvent D Conc. 100.0% 
240.00 Pumps Solvent D Conc. 10.0% 
260.00 Pumps Solvent D Conc. 10.0% 
360.00 Pumps Solvent D Conc. 65.0% 
400.00 Controller Stop  
 
 
Figure 2.  Mobile phase composition profile for the startup conditioning method (▲- 
methanol, ■ - water).  For this method, solvent lines B and C were held at 0% for the 
duration of the run.  The initial mobile phase composition was 65:35 (v/v) 
methanol/water (from solvent line A).  After the 400 minute run, the system returned to 
the initial mobile phase composition.   
The system was then stored in 65:35 (v/v) methanol/water until use.  Before any 





































mL/min through the column overnight.  To prepare the system for analyses, the analysis 
setup method parameters were set as displayed in Table 5.  Figure 3 illustrates the mobile 
phase composition profile used for the setup method.  Just prior to the end of the 60 
minute run, the pumps were shut off, the setup method was stopped, and the run method 
described in Table 6 was initiated.  Therefore, the system was allowed to equilibrate for 
at least 60 minutes with a mobile phase composition of (A) 0%, (B) 25%, (C) 75%, and 
(D) 0% flowing at 1.0 mL/min before the analysis were performed.  Before each use, the 
mobile phase solvents (water, phosphate buffer, and methanol) were passed through a 
MAGNA-R® nylon-supported plain 0.22 µm filter using a vacuum filtration apparatus 
and were degassed by holding the filtered solvent under a vacuum for at least 20 minutes.  
Acetonitrile was passed through a Teflon-laminated 0.22 µm filter using a vacuum 
filtration apparatus and was degassed by holding the filtered solvent under vacuum for at 
least 20 minutes. 
Table 5 
HPLC mobile phase composition and pump parameters used for the system analysis setup 
program (setup method).  The pump mobile phase configuration was:  solvent line A - 
HPLC-grade water, solvent line B - HPLC- acetonitrile, solvent line C - phosphate buffer, 
and solvent line D - HPLC-grade methanol.  The initial mobile phase composition was 
65:35 (v/v) methanol (from solvent line D)/water (from solvent line A) at a 0.1mL/min 
flow rate.  Conc. = concentration of designated solvent. 
Time Module Action Value 
0.01 Pumps Total Pump A Flow 1.00 mL/min 
45.00 Pumps Solvent C Conc. 75.0% 
45.00 Pumps Solvent B Conc. 25.0% 
60.00 Controller Stop  
 
40 
Figure 3.  Mobile phase composition profile for the setup method (▲- methanol, ■ - 
water, ♦ - phosphate buffer, ● - acetonitrile).  For this method the initial mobile phase 
composition was 65:35 (v/v) methanol (from solvent line D)/water (from solvent line A).  
The final mobile phase composition was (A) 0%, (B) 25%, (C) 75%, and (D) 0% flowing 
at 1.0 mL/min. 
The system was prepared for sample analysis by initiating the run method given 
in Table 6.  Figure 4 illustrates the mobile phase composition profile used for the run 
method.  The following mobile phase solvent configuration was held for the analyses: 
solvent line A - HPLC-grade water, solvent line B - HPLC-grade acetonitrile, solvent line 
C - phosphate buffer, and solvent line D - HPLC-grade methanol.  The system initial 
composition of (A) 0%, (B) 25%, (C) 75%, and (D) 0% flowing at 1.0 mL/min was held 
for four minutes, a linear gradient was then used to change the mobile phase to 









































HPLC mobile phase composition and pump parameters used for the system analysis (run 
method).  The pump mobile phase configuration was:  solvent line A - HPLC-grade 
water, solvent line B - HPLC- acetonitrile, solvent line C - phosphate buffer, and solvent 
line D - HPLC-grade methanol.  The initial solvent composition was (A) 0%, (B) 25%, 
(C) 75%, and (D) 0% flowing at 1.0 mL/min.  Conc. = concentration of designated 
solvent. 
Time Module Action Value 
0.01 Pumps Total Pump A Flow 1.00 mL/min 
4.00 Pumps Solvent C Conc. 75.0% 
4.00 Pumps Solvent B Conc. 25.0% 
14.00 Pumps Solvent C Conc. 50.0% 
14.00 Pumps Solvent B Conc. 50.0% 
16.00 Pumps Solvent C Conc. 5.0% 
16.00 Pumps Solvent B Conc. 95.0% 
18.00 Pumps Solvent C Conc. 75.0% 
18.00 Pumps Solvent B Conc. 25.0% 




Figure 4.  Mobile phase composition profile used for the run method (♦ - phosphate 
buffer, ● - acetonitrile).  For this method the initial mobile phase composition was (A) 





































The secondary mobile phase was maintained ten minutes into the run (14 minute 
mark), at which time a linear gradient was used to change the mobile phase of 
phosphate:acetonitrile from (50:50) to (5:95) over the course of the next two minutes (16 
minute mark).  This phase was maintained for two minutes (18 minute mark) and then the 
mobile phase returned via a linear gradient to the initial conditions 
(phosphate:acetonitrile (75:25), 20 minute mark).  The photo diode-array detector 
absorbance wavelength range was set to 328-342 nm, all other settings were set to 
program defaults.  The fluorescence detector SPD-10Avp UV (Shimadzu Co., Japan) 
used for excitation/emission wavelengths was maintained at 470/550 nm, the gain was 
raised to 16X, and all other settings were set to program defaults.  The detector lamps 
were turned on a minimum of one hour prior to analysis to allow for proper stabilization.  
Data analysis was performed using Shimadzu CLASS-VP 5.0 data analysis software 
(Shimadzu Co., Japan).  Quantification of DOX in LV samples was determined from the 
peak area of each component relative to calibration standard curve displayed in Figure 5. 
 
Figure 5.  Doxorubicin standard curve with daunorubicin.  The y-intercept equals 0.309x 









































Dox Concentration (ng/ml) 
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Preparations of Solutions 
HPLC mobile phase stock phosphate buffer (100 mM (0.1 M) NaH2PO4).  To 
make a total volume of 0.5 L, 6.9 g of solid sodium phosphate monobasic (NaH2PO4) was 
dissolved in approximately 400 mL of HPLC-grade water.  The solution was then placed 
in a 500 mL volumetric flask and diluted to volume with HPLC-grade water.  The buffer 
solution was passed through a 0.22 nylon filter and stored in an amber bottle at 4 °C. 
Running phosphate buffer (10 mM (0.01 M) NaH2PO4).  To make a total volume 
of 1.0 L, 100.0 mL of stock phosphate buffer (0.1 M NaH2PO4) was diluted in 
approximately 600 mL of HPLC-grade water and the pH was adjusted to 3.0 using 0.01 
M phosphoric acid (0.01 M phosphoric acid was made by adding 0.17 mL of 14.7 M 
phosphoric acid to 250.0 mL of HPLC grade water).  The solution was then placed in a 
1.0 L volumetric flask and diluted to volume with HPLC-grade water.  The buffer 
solution was passed through a 0.22 nylon filter and stored in a clear bottle at 4 °C.  
LV tissue-preparation phosphate buffer (0.067 M NaH2PO4  at pH 7.4).  To make 
a total volume of 0.2 L, 134.0 mL of stock phosphate buffer (0.1 M NaH2PO4) was 
diluted in approximately 150 mL of HPLC-grade water and the pH will be adjusted to 7.4 
using 5 M NaOH.  The solution was then placed in a 200 mL volumetric flask and diluted 
to volume with HPLC-grade water.  The buffer solution was passed through a 0.22 nylon 
filter and stored in a clear bottle at 4 °C. 
Statistical Analysis 
Group data are reported as mean (M) ± standard error of mean (SEM).  To 
determine significant differences in ex vivo and in vivo cardiac function, a three-way 
(drug X exercise X time) multiple analysis of variance (MANOVA) was used.  The 
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dependent variables of in vivo function are M-VTI, M-Vmax, M-Vmean, A-VTI, A-Vmax, A-
Vmean, and FS.  The ESP, EDP, LVDP, dP/dtmax, and dP/dtmin were used as dependent 
variables of ex vivo function.  To determine significant differences in DOX accumulation, 
a two-way (exercise X time) analysis of variance (ANOVA) was used.  Individual means 
of all DOX groups were then compared to the SED+SAL control mean using independent 
sample t-tests.  A significant level of p < 0.05 was used for all statistical analyses.  
Statistical Analysis System (SAS; SAS Institute Inc., Cary, North Carolina) software was 























 The purpose of this study was to determine the effects of exercise preconditioning 
on cardiac DOX accumulation and to what extent it is related to DOX-mediated cardiac 
dysfunction.  In addition, an HPLC based method was used for a time-course 
determination of DOX clearance in rat left ventricular tissue. 
General Observations 
Nineteen animals died during the experiment (SED+DOX, n = 6; TM+DOX, n = 
7; WR+DOX, n = 7).  Therefore, the mortality rate in the SED+DOX group was 
approximately 9% (6 of 67) and the mortality rate was approximately 11% in both the 
TM+DOX and WR+DOX groups (7 of 65).  Running distances for WR+DOX groups 
were recorded weekly (Figure 6) and peaked at 49718 ± 17925 m during week 5.  Using 
the previously described HPLC method, mean DOX retention time for all samples was 
6.47 minutes and mean DAUN retention time was 8.78 minutes.  Typical chromatograms 
of sedentary and exercise groups 1 day post DOX exposure are shown in Figure 7.  
Figure 8 displays typical chromatograms of sedentary and exercise groups 7 days 




























































Figure 7. Chromatogram of SED+DOX 1 day post (A) and TM+DOX 1 day post (B) 
DOX exposure analyzed by the proposed HPLC method
 
 
Figure 8. Chromatogram of SED+DOX 7 day (A) and WR+DOX 7 day (B) post DOX 





























In Vivo Cardiac Function 
The selected in vivo variables M-VTI, M-Vmax, M-Vmean, A-VTI, A-Vmax, A-Vmean 
and FS are displayed in Figures 9-15.  The main effect of DOX treatment on in vivo 
cardiac function was significantly different across all groups, F (9, 110) = 2.81, p = 
0.0052.  A post hoc test was used to determine which group’s in vivo function was 
different.  A significant difference for in vivo function was observed between SED+SAL 
and SED+DOX, F (9, 110) = 2.81, p < 0.0052.  Likewise, a significant difference for in 
vivo function was observed between SED+SAL and TM+DOX, F (9, 110) = 13.03, p < 
0.0001 and between SED+SAL and WR+DOX, F (9, 110) = 9.09, p < 0.0001.   
For in vivo cardiac function there was a significant exercise effect, F (18, 220) = 
6.46, p = 0.0001.  However, post hoc testing revealed no significant differences existed 
between SED+DOX and TM+DOX, SED+DOX and WR+DOX, or TM+DOX and 
WR+DOX, p > 0.05.  Additionally, a significant effect of time following DOX treatment 
on in vivo cardiac function was observed for all groups F (9, 110) = 3.14, p = 0.0021. 
Doppler blood flow measurements were obtained from the mitral valve to assess 
the LV diastolic functional changes for all experimental groups and individual t-tests for 
in vivo variables were performed for comparisons to SED+SAL.  DOX treatment 
significantly impaired M-VTI in SED+DOX groups at 3, 5, 7 and 9 days when compared 
to SED+SAL (Figure 9, p < 0.05).  However, the impairment was less obvious in 
TM+DOX and WR+DOX groups.  When compared to SED+SAL, M-VTI was only 
reduced 5 days post DOX treatment in WR+DOX while TM+DOX groups were impaired 
at 7 and 9 days post exposure.  Similar to M-VTI, mitral maximal and mean blood flow 
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velocities were significantly reduced in the SED+DOX groups when compared to 
SED+SAL (Figures 10-11, p < 0.05); however, M-Vmax and M-Vmean in TM+DOX and 
WR+DOX groups were not statistically different from the SED+SAL group at any time 
point (p > 0.05).  
Doppler measurements obtained at the aortic valve revealed that DOX treatment 
significantly impaired A-VTI in SED+DOX groups at 3 and 7 days when compared to 
SED+SAL (Figure 12, p < 0.05).  With the exception of TM+DOX 1 day post DOX 
treatment, A-VTI in TM+DOX and WR+DOX groups was not significantly reduced 
when compared to SED+SAL (p > 0.05).  Aortic blood flow velocities (A-Vmax and A-
Vmean) were significantly reduced in the SED+DOX group when compared to SED+SAL 
(Figures 13-14, p < 0.05).  However, TM+DOX and WR+DOX groups were not 
statistically different from the SED+SAL group at any time (p > 0.05).  In addition to 
impaired Doppler measurements, DOX significantly impaired FS in the sedentary groups.  
A significant reduction in FS was observed in SED+DOX at all time points when 
compared to SED+SAL (Figure 15, p < 0.05), while FS was not significantly different 
than SED+SAL at any time point for TM+DOX or WR+DOX.   
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Figure 9. In vivo mitral velocity time integral 
*  significant difference from SED+SAL 
 
 
Figure 10. In vivo mitral maximal flow velocity 
*  significant difference from SED+SAL 
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 Figure 11. In vivo mitral mean flow velocity 
*  significant difference from SED+SAL 
 
 Figure 12. In vivo aortic velocity time integral 
*  significant difference from SED+SAL 
 










































* * * 
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 Figure 13. In vivo aortic maximal flow velocity 
*  significant difference from SED+SAL 
 
 Figure 14. In vivo aortic mean flow velocity 
*  significant difference from SED+SAL 
 

























































 Figure 15. In vivo fractional shortening 
*  significant difference from SED+SAL 
 
 
Ex Vivo Cardiac Function 
Following echocardiographic measurements, LV function was analyzed using an 
isolated working heart apparatus.  This model allows for ex vivo LV function analysis 
without intrinsic influence from the nervous and endocrine systems.  The selected ex vivo 
variables ESP, EDP, LVDP, dP/dtmax and dP/dtmin are displayed in Figures 16-20 
(unpaced) and Figures 21-25 (paced).  The main effect of DOX treatment on ex vivo 
cardiac function was significantly different across all groups, F (30, 479.11) = 2.68, p < 
0.0001.  A post hoc test was used to determine which group’s ex vivo function was 
different.  A significant difference for ex vivo function was observed between SED+SAL 
and SED+DOX, F (10, 163) = 2.17, p = 0.0222.  Additionally, a significant difference for 
ex vivo function was observed between SED+SAL and TM+DOX, F (10, 163) = 4.77, p 
< 0.0001 and between SED+SAL and WR+DOX, F (10, 163) = 3.35, p = 0.0005. 
For ex vivo cardiac function there was a significant exercise effect, F (20, 326) = 
3.06, p < 0.0001.  Post hoc testing revealed a significant difference existed between 




















SED+DOX and TM+DOX groups, F (10, 163) = 2.23, p = 0.0186.  However, no 
significant differences were observed between SED+DOX and WR+DOX groups, F (10, 
163) = 1.66, p = 0.0944; or TM+DOX and WR+DOX groups, F (10, 163) = 1.25, p = 
0.2625.  Additionally, a significant effect of time following DOX treatment on ex vivo 
cardiac function was observed for all groups F (10, 163) = 11.45, p < 0.0001. 
Unpaced Data 
Unpaced pressure measurements were obtained to assess the LV functional 
changes for all experimental groups and individual t-tests for ex vivo variables were 
performed for comparisons to SED+SAL.  DOX treatment alone significantly impaired 
ESP in SED+DOX groups at 5, 7 and 9 days when compared to SED+SAL (Figure 16, p 
< 0.05).  However, the decrement was less pronounced in TM+DOX and WR+DOX 
groups.  When compared to SED+SAL, ESP was significantly higher 1 day post DOX 
treatment (p < 0.05).  The reduction at days 7 and 9 in TM+DOX and day 9 in the 
WR+DOX was significant when compared to SED+SAL (Figure 16, p < 0.05).  
Interestingly, EDP was not significantly different between SED+SAL and SED+DOX 
(Figure 17, p > 0.05).  However, when compared to SED+SAL, EDP was significantly 
lower at day 1 in TM+DOX and significantly higher at day 3, while WR+DOX was 
significantly higher 1 day post DOX treatment.   
Similar to ESP, DOX treatment alone significantly impaired LVDP in SED+DOX 
groups at 5, 7 and 9 days when compared to SED+SAL (Figure 18, p < 0.05).  However, 
the decrement was less pronounced in TM+DOX and WR+DOX groups.  When 
compared to SED+SAL, LVDP was significantly higher 1 day post DOX treatment (p < 
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0.05).  The reduction at 7 and 9 days in the TM+DOX groups and day 9 in the WR+DOX 
was significant when compared to SED+SAL (Figure 18, p < 0.05). 
In SED+DOX groups, at 5 and 9 days, a significant impairment of dP/dtmax and 
dP/dtmin was observed when compared to SED+SAL (Figure 19 and Figure 20, 
respectively, p < 0.05).  However, dP/dtmax in TM+DOX at day 1 was significantly 
greater than SED+SAL (p < 0.05).  The WR+DOX groups at 5 and 9 days displayed a 
significant impairment of dP/dtmax when compared to SED+SAL (Figure 19, p < 0.05), 
while the impairment was not evident in TM+DOX until 9 days post DOX treatment.  At 
the 1 day time point, TM+DOX and WR+DOX displayed improved dP/dtmin when 
compared to the SED+SAL group (Figure 20, p < 0.05).  When compared to SED+SAL, 
impairment was evident at the 7 day time point in TM+DOX and day 9 in TM+DOX and 
WR+DOX (Figure 20, p < 0.05).  
 Figure 16. Unpaced ex vivo end systolic pressure 
*  significant difference from SED+SAL 
  



































Figure 17. Unpaced ex vivo end diastolic pressure 
*  significant difference from SED+SAL 
 Figure 18. Unpaced ex vivo left ventricular pressure development 
*  significant difference from SED+SAL 
 
 






























































 Figure 19. Unpaced ex vivo maximal rate of pressure development 
*  significant difference from SED+SAL 
 Figure 20. Unpaced ex vivo maximum rate of pressure decline 
*  significant difference from SED+SAL 
 
Paced 240 Data 
To obtain standardized LV pressure measurements, hearts were paced at 240 
beats/min following the collection of unpaced data.  DOX treatment alone significantly 
impaired ESP in SED+DOX groups at all the measured time points when compared to 
SED+SAL (Figure 21, p < 0.05).  However, the decrement did not occur in TM+DOX 






























































until days 7 and 9.  In contrast to TM+DOX, WR+DOX displayed significant impairment 
when compared to SED+SAL at 3, 5, 7, and 9 days (Figure 21, p < 0.05).  Comparable to 
unpaced EDP, paced EDP was not significantly different between SED+SAL and 
SED+DOX (Figure 22, p > 0.05).  However, when compared to SED+SAL, EDP was 
significantly lower at day 1 in TM+DOX and significantly higher at day 3, while 
WR+DOX was significantly higher 1 day post DOX treatment. 
Similar to ESP, DOX treatment alone significantly impaired LVDP in SED+DOX 
groups at 1, 3, 5, 7 and 9 days (Figure 23, p < 0.05 vs. SED+SAL).  When compared to 
SED+SAL, LVDP was significantly lower 3, 7, and 9 day post DOX treatment in 
TM+DOX and at 3, 5, and 9 days post exposure in WR+DOX (p < 0.05).  At 3, 5, 7 and 9 
days, SED+DOX, displayed a significant impairment of dP/dtmax when compared to 
SED+SAL (Figure 24, p < 0.05).  However, TM+DOX displayed significant differences 
in dP/dtmax at 3, 7 and 9 days (p < 0.05 vs. SED+SAL).  Significant impairment of 
dP/dtmax in WR+DOX was observed at 3, 5 and 9 days (p < 0.05 vs. SED+SAL).  
Impairment of dP/dtmin occurred in SED+DOX at 5, 7 and 9 days (Figure 25, p < 0.05 vs. 
SED+SAL).  However, dP/dtmin impairment in TM+DOX and WR+DOX occurred at 3 
and 9 days post DOX treatment (Figure 25, p < 0.05 vs. SED+SAL). 
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Figure 21. Paced (240) ex vivo end systolic pressure 
*  significant difference from SED+SAL 
   
 
Figure 22. Paced (240) ex vivo end diastolic pressure 
*  significant difference from SED+SAL 
 

























































 Figure 23. Paced (240) ex vivo left ventricular pressure development 
 *  significant difference from SED+SAL 
 Figure 24. Paced (240) ex vivo maximum rate of pressure development 
*  significant difference from SED+SAL 































































Figure 25. Paced (240) ex vivo maximum rate of pressure decline 




After all functional analyses were performed, LV samples were isolated and flash 
frozen in liquid nitrogen.  Twenty-four hours following sacrifice, cardiac DOX 
accumulation was analyzed using HPLC.  All data are presented in Figure 26.  DOX 
accumulation was significantly different between groups, F (2,145) = 40.38, p < 0.001.  
A post hoc test was used to determine which group’s DOX accumulation was different.  
The greatest accumulation of DOX was observed in SED+DOX 1 day post injection.  
When compared to SED+DOX (day 1), DOX accumulation in TM+DOX (day 1) and 
WR+DOX (day 1) groups was significantly reduced (Figure 26, p < 0.05). 
Similarly, DOX accumulation in SED+DOX at both 3 and 5 days was 
significantly greater than both TM+DOX and WR+DOX at 3 and 5 days, respectively (p 
<0.05).  DOX accumulation in TM+DOX and WR+DOX groups was non-existent at both 

































7 and 9 days.  Because DOX accumulation remained elevated in SED+DOX at 7 days, it 
was significantly greater than TM+DOX and WR+DOX groups (p < 0.05).  Unlike the 
exercised groups DOX was not completely cleared from the LV until 9 days after 
treatment.  DOX accumulation was not significantly different between TM+DOX and 
WR+DOX at any time point (p > 0.05). 
 
 
Figure 26. Accumulation of DOX in rat LV tissue. 
* Significant difference from SED+DOX 
 
Summary 
 Using the described HPLC based method, DOX accumulation was successfully 
quantified in the LV of female rats.  In this study, DOX-induced chronic cardiotoxicity 
resulted in both in vivo and ex vivo cardiac dysfunction.  However, 10 weeks of either 
involuntary or voluntary exercise preconditioning preserved cardiac function.  Significant 










































differences were observed between sedentary and exercise groups for DOX 
accumulation, suggesting that reduced DOX accumulation may be one of the underlying 




























The purpose of this study was to determine if exercise preconditioning reduces 
cardiac DOX accumulation, thereby providing a possible mechanism to explain the 
cardioprotective effects of exercise against DOX cardiotoxicity.  The results indicate that 
exercise had a profound effect on DOX accumulation as evidenced by significant 
decreases in LV DOX accumulation 1, 3, 5, and 7 days after injection.  Additionally, 
DOX treatment resulted in significant cardiac function impairment at 1, 3, 5, 7, and 9 day 
time points when compared to SED+SAL.  Ten weeks of exercise preconditioning prior 
to DOX treatment attenuated these responses, suggesting that exercise-mediated 
cardioprotection is afforded by decreases in cardiac DOX accumulation.  
Time-course of Doxorubicin Cardiotoxicity 
DOX is a highly effective antineoplastic agent and used to treat a variety of 
cancers including breast, bladder, Hodgkin’s and non-Hodgkin’s lymphomas.  However, 
its use clinically is limited by a dose-dependent cardiotoxicity that can subsequently lead 
to heart failure (Lipshultz, et al., 2005; Singal, et al., 2000).  The acute form of 
cardiotoxicity often develops within hours or days following DOX treatment (Ferrans, et 
al., 1997; Tokarska-Schlattner, et al., 2006).  Patients receiving DOX may display signs 
of acute cardiotoxicity including EKG changes, hypotension, myocarditis and pericarditis 
(Schimmel, et al., 2004).  In experiments using a rat model, indices of DOX-mediated 
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cardiotoxicity are commonly reported as impairments to in vivo and ex vivo cardiac 
function variables (Hydock, Lien, & Hayward, 2009; Hydock, et al., 2008; Hydock, et al., 
2010).  This investigation examined the effects of DOX on in vivo and ex vivo cardiac 
function over time.  The selected variables measured in the current investigation are 
indicative of systolic (FS, A-Vmax, A-Vmean, ESP, LVDP and dP/dtmax) and diastolic 
(M-Vmax, M-Vmean, EDP and dP/dtmin) cardiac function.  Cardiac dysfunction induced 
by DOX treatment resulted in reduced Doppler blood flow measurements, decreased FS, 
ESP, LVDP, and dP/dtmax, and increased dP/dtmin at 1, 3, 5, 7 and 9 days post treatment 
with a greater tendency of impaired function as time progressed. 
Cardiac dysfunction has been reported to occur 10 days (Hydock, et al., 2008), 7 
days (Hayward & Hydock, 2007), 5 days (Chicco, Hydock, et al., 2006; Chicco, 
Schneider, et al., 2006; Hydock, Lien, & Hayward, 2009; Wonders, et al., 2008), and 
even 1 day (Neilan, et al., 2006) post DOX treatment with cumulative doses varying from 
10-20 mg/kg.  However, a cumulative dose of 9 mg/kg (Monti, Prosperi, Supino, & 
Bottiroli, 1995) has been shown to decrease LVDP 10 days following DOX exposure and 
7.5 mg/kg (Sacco, et al., 2003) was responsible for a decline in dP/dtmax 3 days post DOX 
treatment.  It is understood that both the cumulative dose and time course of DOX 
treatment play an important role in the onset and degree of cardiac dysfunction (Minotti, 
Menna, et al., 2004).  Hayward and Hydock (2007) assessed the effects of different DOX 
dosing schedules on in vivo cardiac function in male rats.  The time course of cardiac 
dysfunction was clearly affected by the DOX treatment regimen.  In the current study, 
female rats received the same DOX regimen (10 mg/kg bolus i.p. injection of DOX) 
which resulted in a similar reduction in FS (-24%) 7 days post DOX treatment when 
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compared to the previously reported reduction of FS (-22%) in male rats (Hayward & 
Hydock, 2007).  Furthermore, previous studies have reported comparable declines in 
Doppler blood flow measurements in rats receiving a 10-15 mg/kg cumulative dose of 
DOX  evidenced by a significant decrease in M-Vmax and M-Vmean (Hydock, et al., 2010), 
A-TVI (Hayward & Hydock, 2007), A-Vmax and A-Vmean (Hayward & Hydock, 2007; 
Hydock, Lien, & Hayward, 2009). 
In this investigation, 10 mg/kg of DOX significantly impaired not only in vivo 
cardiac function but also ex vivo cardiac function in female rats 3, 5, 7 and 9 days after 
treatment.  Similarly, in vivo and ex vivo measurements of cardiac function in rats 
receiving a 10 mg/kg bolus of DOX, showed that at 5 and 10 days post treatment, there 
were significant decreases in Doppler measurements, dP/dtmax and LVDP (Hydock, et al., 
2008).  The SED+DOX group displayed classic signs of DOX cardiotoxicity including 
reductions in ESP, LVDP, dP/dtmax and impaired dP/dtmin.  These general observations 
corroborate with findings reported in several other studies of DOX-mediated 
cardiotoxicity (Chicco, Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et 
al., 2006; Hydock, Lien, Jensen, Schneider, & Hayward, 2011; Hydock, et al., 2008; 
Hydock, et al., 2010; Wonders, et al., 2009; Wonders, et al., 2008).  Numerous 
mechanisms are likely to contribute to the dysfunction observed with DOX treatment in 
the sedentary rats.  Previous studies suggest DOX treatment results in the formation of 
RONS (Sarvazyan, 1996), apoptosis (Kumar, Kirshenbaum, Li, Danelisen, & Singal, 
1999), mitochondrial dysfunction (Oliveira, Santos, & Wallace, 2006) and impaired Ca2+ 
handling in the cardiomyocyte (Hirano, Agata, Iguchi, & Tone, 1995; Kim, et al., 2006).  
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Collectively, these mechanisms are thought to have the greatest contribution to DOX-
mediated cardiotoxicity.   
Effects of Exercise on Doxorubicin  
Cardiotoxicity 
 
In the present study, a 10 mg/kg bolus dose of DOX resulted in significant in vivo 
and ex vivo cardiac dysfunction in sedentary animals 1, 3, 5, 7 and 9 days post DOX 
treatment.  This dysfunction was associated with DOX accumulation in cardiomyocytes.  
Conversely, rats that participated in either voluntary wheel running or treadmill exercise 
for 10 weeks did not exhibit the same degree of cardiac dysfunction.  Furthermore, they 
displayed significantly less DOX accumulation at 1, 3, 5 and 7 days following DOX 
administration.  Previous studies have determined that exercise preconditioning can 
attenuate DOX-induced cardiotoxicity (Chicco, Schneider, et al., 2006; Hydock, et al., 
2011; Hydock, et al., 2008; Hydock, et al., 2010; Wonders, et al., 2009).  As expected, 
general observations from the current investigation coincide with previous studies that 
used exercise preconditioning to mitigate the cardiotoxic effects of DOX. 
A novel investigation conducted by Chicco et al., (2005) was the first to provide 
evidence supporting chronic voluntary exercise prior to DOX exposure in the attenuation 
of cardiac dysfunction.  Until that time, experiments had shown promise for exercise-
induced cardioprotection against DOX cardiotoxicity; however, cardiac function was not 
addressed (Ascensao, Magalhaes, et al., 2005b; Combs, Hudman, & Bonner, 1979; Ji & 
Mitchell, 1994).  A follow up study was conducted by Chicco et al., (2006) in which rats 
trained on a treadmill for 12 weeks.  Five days following a 15 mg/kg bolus i.p. injection 
of DOX, cardiac function was assessed.  Results indicated that LVDP, dP/dtmax, and 
dP/dtmin were significantly impaired in sedentary DOX treated rats compared to exercise 
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trained rats.  Collectively, results from these studies suggest that cardioprotection from 
DOX-induced dysfunction is achieved regardless of exercise modality.  Therefore, results 
from the current investigation were as expected and voluntary wheel running afforded 
similar cardioprotection as treadmill exercise.  Additionally, it was hypothesized that 
both treadmill and wheel running exercise prior to DOX treatment would result in less 
DOX accumulation when compared to sedentary rats.  Thus, exercise preconditioning 
would not only improve cardiac function but also offer cardiomyocytes direct protection 
from DOX cardiotoxicity by reducing the degree of DOX exposure.   
The use of voluntary exercise as a training regimen has been shown to increase 
the sarcomere length-tension relationship, cardiac contractility (Lambert & Noakes, 
1990; Natali, Turner, Harrison, & White, 2001; Natali, et al., 2002) and oxygen 
consumption (Lambert & Noakes, 1990; Yano, Yano, Kinoshita, & Tsuji, 1997).  Similar 
findings have been reported with treadmill exercise, evidenced by increased 
cardiomyocyte contractility and oxygen consumption (Wisloff, Helgerud, Kemi, & 
Ellingsen, 2001; Wisloff, Loennechen, et al., 2001).  Furthermore, the cardiovascular 
adjustments between the two modalities appear to be similar (Yancey & Overton, 1993).  
In the current study, both preconditioning modalities resulted in cardioprotection from 
DOX-mediated dysfunction and less DOX accumulation compared to SED+DOX.  
Additionally, DOX accumulation was not affected by modality evidenced by similar 
observations of LV DOX in TM+DOX and WR+DOX groups.  Thus, exercise 
preconditioning, independent of modality, protected against cardiotoxicity as a result of 
reduced DOX accumulation.  
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It has previously been suggested that subtle differences in exercise-mediated 
stress exist between voluntary and involuntary exercise (Moraska, Deak, Spencer, Roth, 
& Fleshner, 2000; Moraska & Fleshner, 2001).  Moraska et al., (2001) reported that 
voluntary wheel running can reduce the deleterious effect of stress on immune function 
and involuntary treadmill training (Moraska, et al., 2000) elevated lymphocyte nitrite 
concentrations and suppressed lymphocyte proliferation, common immune responses, as 
the result of chronic stress.  Thus, the exercise intensity from the aforementioned 
modalities may result in different chronic stress. 
In the current study, exercise preconditioning prevented the in vivo and ex vivo 
cardiac dysfunction observed with DOX treatment alone.  Several mechanisms may be 
responsible for the observed cardioprotective effects of exercise preconditioning.  Most 
noteworthy, evidence that cardiac DOX accumulation was significantly lower in 
TM+DOX and WR+DOX hearts at 1, 3, 5, and 7 day time points suggest that a reduction 
in cardiac DOX exposure may be responsible for the preservation in cardiac function. 
Mechanisms of Cardioprotection 
This study demonstrated, for the first time, that exercise mitigated DOX 
accumulation and afforded cardioprotection.  Determining the underlying mechanism 
behind exercise-induced cardioprotection from DOX has been of great interest.  The 
observed reduction in LV DOX accumulation, as the result of exercise preconditioning, 
offers the greatest contribution to the explanation of exercise-mediated cardioprotection 
against DOX-induced cardiotoxicity.  While these results confirm an exercise effect on 
DOX accumulation in the heart, the exact mechanisms responsible for the exercise-
mediated reduction of LV DOX are still unknown.  Therefore, the following discussion 
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will focus on the theoretical foundation for an exercise-induced reduction in DOX 
accumulation in cardiomyocytes. 
Doxorubicin Accumulation 
One potential explanation for less DOX accumulation in exercise preconditioned 
rats may be due to increased DOX extrusion as the result of an upregulation of ABC 
transporters.  It is commonly accepted that cancer cells have the ability to develop a drug 
resistance phenotype (Shen, et al., 2008; Sorokin, 2004).  Several mechanisms are 
thought to contribute to the drug resistance phenotype including increased drug extrusion, 
decreased permeability, altered drug metabolism and deactivation (Davin-Regli, et al., 
2008).  Additionally, non-cancerous cells, such as cardiomyocytes, display drug resistant 
mechanisms as a means for inherent cytoprotection (Jungsuwadee, et al., 2009).  For 
example, cardiomyocytes normally express ABC transporters to allow or deny access of 
nutrients and xenobiotics.  Recently, numerous reports involving experimental 
enhancement of ABC transporters have been shown to effectively pump xenobiotics out 
of the cell (Dazert, et al., 2003; Dong, et al., 2009; Gradilone, et al., 2008; Krause, et al., 
2007; Meissner, et al., 2007; Shen, et al., 2008; Zhang, et al., 2009).  The subfamily 
proteins that are most involved in the transport of xenobiotics, including DOX, are 
multidrug resistance proteins (MDR), MRPs and ABCA.  Specific to location and tissue 
type, MDR and MRPs are sub-categorized (i.e. MDR-1, MRP-1, MRP-2, MRP-3, MRP-
4, MRP-5, and ABCA-1).   
Sub-family ABC transporters including a p-glycoprotein MDR-1 (Beaulieu, 
Demeule, Ghitescu, & Beliveau, 1997; Meissner, et al., 2004), MRP-1, MRP-2 (Rosati, et 
al., 2003), MRP-5 (Dazert, et al., 2003; Meissner, et al., 2007) and ABCA-1 (Nishimura, 
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Naito, & Yokoi, 2004) expression occurs in cardiac tissue.  The aforementioned protein 
transporters may offer some insight to the transport of DOX and the regulation of its 
anticipated toxicities.  Bellamy et al, (1995) reported cardiac DOX accumulation 
increased two-fold in non-tumor bearing mice when treated with a combination of DOX 
and Cyclosporin A, a potent MDR-1 inhibitor.  In addition, a greater degree of 
myocardial insult was observed in mice exposed to the combination of DOX and 
Cyclosporin A than in those mice not receiving the combined treatment.  A similar 
finding was reported in MDR-1 knock-out mice (mdr1a-/-) 24 hours post DOX treatment.  
The accumulation of DOX and DOX-ol were greater than two-fold higher in the hearts of 
(mdr1a-/-) mice when compared to control mice (van Asperen, van Tellingen, Tijssen, 
Schinkel, & Beijnen, 1999).  In vitro inhibition of ABCA-1 genes via extracellular signal-
regulated kinases (ERK) resulted in increased DOX accumulation determined by 
fluorescence microscopy (Shukla, et al.). Furthermore, isolated cardiomyocytes from 
Sprague-Dawley rats that were treated with calcium channel blockers in vitro to reverse 
the multidrug resistant phenotype showed an increased concentration of DOX and 
cardiotoxicity as indicated by increased heart levels of lactate dehydrogenase (Santostasi, 
Kutty, & Krishna, 1991).  Similarly, it has been demonstrated that an enhancement of 
expression and/or activity of ABC transporters in the heart results in a desirable drug 
resistance phenotype (Dell'Acqua, Polishchuck, Fallon, & Gordon, 1999; Granzotto, et 
al., 2004; Magnarin, et al., 2004).  Dell'Acqua et al., (1999) reported transgenic mice that 
overexpressed the MDR-1 gene displayed greater cardioprotection from a 30 mg/kg 
cumulative dose of DOX when compared to control mice.  Collectively, these studies 
have demonstrated that a blockade or enhancement of ABC transporters significantly 
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influences extrusion of DOX and/or DOX-ol, and the subsequent drug exposure is related 
to heart damage.  This notion confirms the important role of ABC transporters in 
cardioprotection from DOX-mediated cardiotoxicity. 
Previous work suggests that exercise training is capable of increasing expression 
of ABC transporters including ABCA-1 (Ghanbari-Niaki, Khabazian, Hossaini-Kakhak, 
Rahbarizadeh, & Hedayati, 2007; Ghanbari-Niaki, Saghebjoo, & Hedayati, 2010; 
Khabazian, et al., 2009) and MRP-1(Krause, et al., 2007).  Khabazian, et al., (2009) 
reported that exercise-induced increases in ABCA-1 expression were present in adult 
male Wistar rats 2 days following a 12 week treadmill training protocol.  In addition, 
Ghanbari-Niaki, et al., (2007) reported significantly increased ABCA-1 expression in rats 
24 hours post the completion of a 6 week treadmill training protocol when compared to 
sedentary controls.  This suggests that upregulation of ABCA-1 may be an adaptation to 
increased endurance exercise.  However, Ghanbari-Niaki, et al., (2010) recently reported 
increased ABCA-1 mRNA expression in female students who completed a single session 
of circuit-resistance training but the exercise-induced expression was observed in 
lymphocytes not cardiomyocytes.  Furthermore, Krause et al. (2007) reported rats that 
performed 60 minutes of swimming exercise for 1 week displayed a significant increase 
in MRP-1 expression (2.4-fold increase) which translated into a significant increase in 
pumping activity, possibly suggesting that less DOX would reside in cardiomyocytes if 
MRP-1/GS-X pumps were upregulated.  The current investigation did not measure 
ABCA-1 or MRP-1 expression; therefore, the relationship between the aforementioned 
ABC transporters and DOX accumulation in myocardial cells remains unclear.  However, 
it is conceivable to speculate that exercise caused an upregulation of ABC transporters in 
73 
TM+DOX and WR+DOX rat hearts which resulted in greater DOX extrusion and less 
accumulation in the cardiac cell. 
It has also been hypothesized that the accumulation of xenobiotics in target or 
non-target tissues is primarily dependent on a mechanical barrier which influences the 
intracellular concentration of the drug (Davin-Regli, et al., 2008).  In a study by 
Versantvoort (1992), multidrug resistant cells were altered to examine DAUN 
accumulation and membrane permeability.  A 5-fold efflux of DAUN was observed in 
multidrug resistant cells lacking p-glycoproteins compared to controls suggesting other 
mechanisms influenced DAUN accumulation in the MDR cells.  Thus, it is probable that 
the accumulation of DOX, in cardiomyocytes, depends not only on the drug efflux, but 
also DOX influx across the cellular membrane (Han & Zhang, 2004).  Further study is 
necessary to examine the effects of exercise on ABCA-1 and MRP-1 expression and 
determine if induction translates into less DOX accumulation, and a preservation of 
cardiac function from DOX-mediated cardiotoxicity.   
Due to the large number of samples per experimental subgroup, DOX 
concentrations measured during the course of this experiment allowed for greater 
statistical confidence in the obtained results.  DOX accumulation was reduced in all 
experimental groups over the course of 9 days.  This finding is consistent with recent 
DOX pharmacokinetic studies (Ahmed, et al., 2009; Staples, et al., 2010; Urva, et al., 
2009).  DOX accumulation was not detected beyond 7 days of DOX exposure.  Recently, 
Staples, et al., (2010) reported that DOX was still present in rat heart 7 days post 
treatment but could not be detected 8 days post using HPLC.   
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In the present study, understanding the distribution of DOX in cardiac tissue over 
time was also of interest.  It is conceivable that greater DOX exposure (time or 
concentration) to cardiomyocytes would result in greater cardiac insult.  While a 
reduction over time was as hypothesized, the degree of decline was unknown.  The 
SED+DOX (day 3) group displayed a 31% reduction in accumulation from SED+DOX 
(day 1), a 63% reduction was observed in SED+DOX (day 5) compared to SED+DOX 
(day 3), and a 45% reduction was observed in SED+DOX (day 7) when compared to 
SED+DOX (day 5).  The TM+DOX (day 3) group displayed a 47% reduction compared 
to TM+DOX (day 1), a 62% reduction was observed in TM+DOX (day 5) compared to 
TM+DOX (day 3), and no DOX was detected after 7 days post treatment.  Similarly, 
WR+DOX displayed a 47% clearance from day 1 to day 3, a 62% clearance from day 3 
to day 5, and 100% clearance from day 5 to day 7.  At the 9 day time point, DOX was not 
detected in any of the exercised groups.  It appears that the degree of decline, indicated 
by percent change from one time point to another, was not drastically influenced by the 
modality of exercise training.  DOX metabolism was not measured in the current 
investigation.  However, it is plausible that exercise training resulted in elevated drug 
metabolism immediately following exposure.  After i.v. injection in rats and humans 
(Rousseau & Marquet, 2002), DOX has a distributive half-life of about 5 minutes and a 
terminal half-life of 20 to 48 hours (Danesi, Fogli, Gennari, Conte, & Del Tacca, 2002).  
This suggests that DOX uptake by the tissues happens rapidly, while tissue elimination is 
much slower.  DOX is rapidly cleared from the plasma and extensively excreted through 
the biliary pathway following injection (Danesi, et al., 2002; Salvatorelli, et al., 2009).  It 
has been reported that approximately 40% of DOX is excreted in bile and around 5-12% 
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in the urine over the course of 5 days (Danesi, et al., 2002).  It is plausible that the initial 
uptake of DOX in LV tissue of exercise trained rats is reduced due to the upregulation of 
MRP-1, resulting in a greater concentration of DOX in the plasma and reduced 
concentration in the tissue. 
Doxorubicin Metabolism 
Another possible explanation for the reduction of DOX accumulation observed in 
exercise trained rats is altered drug metabolism.  DOX-induced cardiotoxicity occurs 
following exposure of the parent drug and its metabolites (Sacco, et al., 2003).  
Cytoplasmic aldo/keto or carbonyl reductases convert DOX to DOX-ol (Minotti, et al., 
2001).  Doxorubicin is composed of an aglycone (doxorubicinone) and a sugar 
(daunosamine).  Doxorubicinone is a tetracyclic ring system with quinone-hydroquinone 
moieties and a side chain with a carbonyl group at C-13.  One-electron reduction of the 
DOX quinone moiety is followed by redox cycling of oxygen and formation of ROS, 
while a 2-electron reduction of the side-chain carbonyl group results in DOX-ol 
formation (Minotti, et al., 2000; Sacco, et al., 2003).  It has been suggested that the 
secondary alcohol metabolite, DOX-ol, is associated with increased cardiotoxicity.  In a 
study by Olson et al., (1988) DOX-ol exhibited greater acute cardiotoxicity than the 
parent drug DOX evidenced by reduced systolic function and impaired Ca++ handling.  
Additionally, an investigation with overexpression of carbonyl reductases in transgenic 
mice resulted in an increased conversion of DOX to DOX-ol and advanced the 
development of cardiomyopathy (Forrest, Gonzalez, Tseng, Li, & Mann, 2000).  
Furthermore, levels of DOX-ol in the heart have a greater correlation to cardiac 
dysfunction than DOX (Sacco, et al., 2003).  Investigators have suggested that the 
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relationship between the secondary metabolites and cardiotoxicity may be due, in part, to 
the fact that DOX-ol is more polar than DOX and subsequently more likely to accumulate 
in the heart (Forrest, et al., 2000; Minotti, Recalcati, et al., 2004; Sacco, et al., 2003).  
Collectively, these studies have demonstrated that increased DOX metabolism and/or 
DOX-ol formation is related to heart damage suggesting the important role of 
cytoplasmic reductases. 
Evidence, though minimal, has linked exercise training to a reduction in reductase 
enzyme expression which may explain its cardioprotective effects.  Exercise has been 
reported to alter the expression of cytoplasmic reductases.  Following 30 minutes of 
exercise, Aldo-keto reductase family 1, member-3, gene expression was down-regulated 
5 fold (Connolly, et al., 2004).  Similarly, in a recent study by Lee et al., (2011) it was 
reported that exercise training down-regulates Nrf-2, a gene primarily responsible for the 
coding of NAD(P)H quinone oxidoreductase.  NAD(P)H quinone oxidoreductase is a 
sub-family protein to oxidoreductases which are included in the carbonyl reductase 
family.  Furthermore, it has been reported that lower levels of carbonyl reductases results 
in less conversion of DOX to DOX-ol in carbonyl reductase family 1 (cbr1 +/-) knockout 
mice.  Knockout mice (cbr1 +/-) were protected from DOX-cardiotoxicity compared to 
cbr1 +/+ suggesting that a reduction of carbonyl reductase resulted in less DOX-ol 
formation (Olson, et al., 2003). 
The current investigation did not measure the expression of cytoplasmic reductase 
enzymes; therefore, the relationship between exercise and DOX metabolism in 
cardiomyocytes is unknown.  However, reductases play a significant role in metabolizing 
DOX and increasing the cardiotoxic properties of the drug.  Thus, it is conceivable to 
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speculate that TM+DOX and WR+DOX groups produced less secondary alcohol 
metabolites than SED+DOX. 
Secondary Cardioprotective Mechanisms 
Other reports have shown that the protective effects of exercise against DOX 
cardiotoxicity are associated with increased antioxidant enzyme upregulation (Ascensao, 
Magalhaes, et al., 2005b; Chicco, Hydock, et al., 2006), a preservation of SERCA2a 
expression (Lien, et al., 2009), and maintenance of cardiomyocyte ultrastructure 
evidenced by decreased serum cardiac troponin I (Ascensao, Ferreira, Oliveira, & 
Magalhaes, 2006).  Other reports have shown exercise is associated with a preservation 
of myosin heavy chain isoform expression (Hydock, Wonders, et al., 2009), decreased 
lipid peroxidation (Wonders, et al., 2009), upregulation of HSP (Chicco, et al., 2005; 
Chicco, Schneider, et al., 2006), and the attenuation of DOX-mediated increases in 
caspase activity (Wonders, et al., 2009).  It is likely that the aforementioned exercise-
mediated cardioprotecive mechanisms may be explained, in part, by the underlying 
mechanism of reduced DOX accumulation in the left ventricular tissue of the exercised 
animals.   
A large amount of evidence indicates that ischemia-reperfusion and DOX-
mediated cardiac dysfunction are primarily mediated by oxidative stress (Abdel-Wahab, 
et al., 2003; Kalyanaraman, et al., 2002; Kumar, Kirshenbaum, Li, Danelisen, & Singal, 
2001; Patel, Joseph, Corcoran, & Ray, 2010; Sarvazyan, 1996).  In the DOX-induced 
cardiac dysfunction model, it is believed that the elevated myocardial oxidative stress is 
mainly due to increased production of RONS as a result of DOX redox cycling (Minotti, 
Recalcati, et al., 2004).  The enhancement of SOD (Yen, et al., 1996) and endothelial 
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nitric oxide synthase (Kalyanaraman, et al., 2002) status has been shown to lessen the 
oxidative state, thus protecting the heart from DOX toxicity.  In addition to DOX-
mediated cardiotoxicity, oxidative stress appears to play a key role in another cardiac 
dysfunction model, ischemia reperfusion injury (Lennon, et al., 2004; Starnes, Taylor, & 
Park, 2003).  Prior studies have reported that antioxidant supplementation resulted in 
cardioprotection from ischemia reperfusion injury (Coombes, et al., 2000; Hamilton, et 
al., 2003; Powers, DeRuisseau, Quindry, & Hamilton, 2004).  Therefore, in both models, 
a reduced oxidant production appears to provide the myocardium protection and 
contributes to the attenuation of cardiac dysfunction. 
Researchers commonly suggest that the cardioprotective effect of exercise is due, 
in part, to reduced production of ROS and increased antioxidant capacity (Ascensao, 
Ferreira, & Magalhaes, 2007; Powers, Quindry, et al., 2004).  Analysis of the oxidative 
status was not conducted in the present study; thus, the degree of myocardial oxidative 
stress due to DOX treatment is not known.  However, it is plausible that a reduction in 
DOX accumulation mediated by exercise training reduced the amount of DOX-mediated 
RONS.  Gunduz, et al., (2004) suggested that exercise is capable of inducing the 
enhancement of other antioxidant defenses including GPx and CAT.  In a study by 
Kanter et al., (1985) mice were exercise preconditioned for 9 weeks prior to DOX 
treatment.  Interestingly, GPx and CAT activities were significantly increased in the 
trained rats and offered protection from DOX-induced toxicity evidenced by histological 
evaluation of the heart. 
In contrast to primary antioxidant enzymes, it has been suggested that the 
myocardium intrinsically protects itself from oxidative stress via antioxidant enzymes 
79 
including thioredoxin (Berndt, Lillig, & Holmgren, 2007; Holmgren & Lu, 2010) and 
peroxiredoxin (Kumar, Kitaeff, Hampton, Cannell, & Winterbourn, 2009).  A review by 
Berndt, et al., (2007) noted the potential cardioprotective role of thioredoxin and 
thioredoxin reductase and suggested that these enzymes protect against oxidative stress 
and inhibit apoptotic signaling.  Similarly, peroxiredoxin has been reported to reduce 
oxidative stress in the hearts of ischemically injured mice (Kumar, et al., 2009).  
Therefore, in addition to the primary antioxidant enzymes associated with 
cardioprotection it appears the heart may have other oxidative defenses.  Currently, the 
effect of exercise training on thioredoxin and peroxiredoxin in the heart is unknown.  
However, Lappalainen, et al., (2009) reported that 8 weeks of exercise training increased 
brain thioredoxin in male rats.  Thus, it is plausible that exercise-induced changes in one 
or all of these antioxidant systems may contribute to the preservation of cardiac function.  
In addition to antioxidant defense, another explanation for the observed preservation of 
cardiac function in exercise trained rats could be due to an attenuation of mitochondrial 
dysfunction. 
Mitochondria play a vital role in the synthesis of ATP.  From a bioenergetic 
standpoint, it is imperative that the mitochondria synthesize enough ATP to match the 
cellular demand.  When ATP synthesis is insufficient, metabolic demand is not met and 
cellular death may occur (Baines, 2009b; Crompton, 1999).  Under normal physiological 
conditions, oxidative phosphorylation of acetyl coenzyme A (CoA), derived from the 
beta oxidation of fatty acyl-CoA found inside the mitochondrial matrix, is primarily 
responsible for meeting the cellular demand for ATP.  The rate of ATP synthesis is 
controlled largely by oxidative enzymes.  Heart failure is associated with a reduction in 
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key regulatory oxidative enzymes including acyl-CoA dehydrogenase and carnitine 
translocase (Baines, 2009a; Kelly & Strauss, 1994; Roschinger, et al., 2000).  De Sousa, 
et al., (2002), reported that a downregulation in oxidative enzymes exacerbated the shift 
from beta oxidation to glycolysis, suggesting an association between heart failure and 
reduced fatty acid metabolism.  Pellieux et al., (2006) overexpressed angiotensinogen in 
transgenic mice to induce congestive heart failure and reported that fatty acid oxidation 
was compromised.  Recently, evidence has shown that in vitro, rat cardiomyocytes 
exposed to angiotensin II, a modulator in heart failure, reduced fatty acid oxidation 
(Pellieux, Montessuit, Papageorgiou, & Lerch, 2009).  A reduction in fatty acid 
metabolism may lead to mitochondrial dysfunction (van Bilsen, van Nieuwenhoven, & 
van der Vusse, 2009).  However, it was reported that 8 weeks of voluntary wheel running 
exercise attenuated the observed metabolic shift in aortic banded rats (De Sousa, et al., 
2002).  Furthermore, free carnitine, was reported to be increased in exercised trained rats, 
thus contributing to increased fatty acid metabolism (Cha, Kim, & Daily, 2003).  In aortic 
banded pigs, low-intensity interval exercise training inhibited mitochondrial dysfunction 
and preserved LV function (Emter & Baines, 2010).  The aforementioned effects may 
play an important role in the maintenance of mitochondrial biogenetics, improving its 
resistance to ischemic or chemical induced dysfunction.   
In addition to ATP deprivation, the production of ROS in mitochondria can lead 
to mitochondrial dysfunction (Carvalho, et al., 2010; Lumini-Oliveira, et al., 2009; Zhou, 
et al., 2001).  Mitochondrial impairment following either ischemia reperfusion injury 
(Baines, 2009a) or DOX treatment contributes to cardiac dysfunction (Ascensao, et al., 
2007; Ascensao, Lumini-Oliveira, Oliveira, & Magalhaes, 2011).  An increased oxidative 
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state can impair mitochondrial calcium homeostasis (Solem, et al., 1994) and ATP 
synthesis which contributes to the opening of MPTP (Baines, 2009b).  Starnes et al., 
(2007) reported that ROS production was elevated in myocardial mitochondria and 
resulted in less calcium influx following ischemia reperfusion.  Additionally, Marcil et al. 
(2006) reported that mitochondria isolated from rat hearts exposed to anoxia-
reoxygenation injury in vitro resulted in calcium-induced MPTP opening.  Similar to 
reperfusion injury models, DOX treatment results in increased mitochondrial oxidative 
stress due to heavy redox cycling which occurs at complex I (Tokarska-Schlattner, et al., 
2006; Wallace, 2003).  It is believed that mitochondrial calcium homeostasis and MPTP 
impairment is the result of an increased oxidative state (Baines, 2009b; Crompton, 1999).  
Additionally, the intercalation of DOX into mtDNA may also contribute to mitochondrial 
dysfunction.  DOX and other DNA intercalators were reported to intercalate mtDNA and 
caused mtDNA depletion in myocardial cells (Ashley & Poulton, 2009a).  An in vitro 
study by Sarvazyan (1996) indicated that a time-dependent accumulation of DOX 
occurred in the mitochondria of cardiomyocytes.  Thus, it appears that DOX has a high 
affinity for mitochondria and DOX-induced mitochondrial dysfunction facilitates 
destructive events in cardiomyocytes that may contribute to cardiac dysfunction.   
Interestingly, numerous studies have reported that exercise preconditioning results 
in cardiac mitochondrial adaptations that result in reduced ROS production (Kavazis, 
Smuder, Min, Tumer, & Powers, 2010; Starnes, et al., 2007) and MPTP formation (Emter 
& Baines, 2010; Kavazis, et al., 2010; Lumini-Oliveira, et al., 2010; Marcil, Bourduas, 
Ascah, & Burelle, 2006).  In the current investigation, cardioprotection was evident; 
however, mitochondrial function was not determined.  It is plausible, though, that the 
82 
reduced DOX accumulation observed in the exercise trained groups resulted in less 
DOX-mediated mitochondrial dysfunction, thereby providing a theoretical basis for the 
observed preservation of cardiac function.  Further study is needed to explore the 
physiological significance of any interaction between physical activity and DOX 
accumulation on mitochondrial dependent ROS, ATP synthesis, calcium homeostasis, 
and MPTP opening in cardiomyocytes. 
Summary and Conclusions 
In the current investigation, DOX treatment resulted in acute cardiotoxicity.  
Impaired systolic and diastolic cardiac function was observed both in vivo and ex vivo.  
However, 10 weeks of exercise preconditioning resulted in a preservation of cardiac 
function.  Additionally, HPLC was successfully used to quantify DOX accumulation in 
LV tissue of female rats at multiple time points.  Voluntary wheel running activity or 
involuntary treadmill exercise performed prior to DOX treatment resulted in less LV 
DOX accumulation.  This is believed to be the first study to investigate the 
cardioprotective mechanism of exercise-mediated DOX accumulation.  These findings 
suggest that regular physical activity may be a valuable complementary therapy to offset 
cardiotoxicities that often occur in cancer patients receiving DOX treatment.  
Furthermore, cancer survivors participating in exercise training programs may be able to 
better tolerate drug exposure, resulting in greater survival and an improvement in their 
quality of life.  
Limitations and Future Study 
Based on the results of the current investigation, the following are limitations of 
this study and recommendations for future research.   
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1) This study employed the chemotherapeutic agent DOX to cancer-free rats to 
investigate the effects of exercise, DOX, and time on cardiac function and DOX 
accumulation.  This investigation confirmed that exercise can reduce DOX accumulation 
in the LV.  Using a tumor-bearing animal model would be of interest to determine the 
effect of exercise on DOX accumulation in tumor cells.  Furthermore, future studies 
could use a tumor-bearing model to confirm the results of this investigation and 
additionally determine whether exercise affects the efficacy of this antineoplastic agent. 
2) In this study, 10 weeks of either involuntary or voluntary exercise 
preconditioning reduced LV DOX accumulation and preserved cardiac function in female 
rats.  In addition to chronic exercise preconditioning, short term exercise has also been 
reported to be cardioprotective against DOX cardiotoxicity (Jensen, et al., 2009; Kavazis, 
et al., 2010).  Thus, the possibility exists that short term exercise may also result in 
decreased DOX accumulation and preservation of cardiac function.  Future study is 
needed to determine the effect of short term exercise on DOX accumulation and cardiac 
function. 
3) Using the described HPLC based method, DOX accumulation was successfully 
quantified in the LV of female rats.  However, DOX metabolites such as DOX-ol, 
aglycone-DOX, and aglycone-DOXol were not quantified.  Evidence suggests DOX 
metabolites are cardiotoxic and may have an even greater contribution to DOX-mediated 
cardiotoxicity (Minotti, Menna, et al., 2004).  Therefore, it would be of great interest to 
investigate the effect of exercise on the accumulation of DOX metabolites. 
4) In this study, the protective effects of exercise were associated with a reduction 
in DOX accumulation.  Recent evidence shows that ABC transporters such as MRP-1 are 
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responsible for the cellular efflux of DOX (Dong, et al., 2009; Krause, et al., 2007; Shen, 
et al., 2008; Zhang, et al., 2009).  In future studies, it may be of interest to determine if 
treadmill or wheel running exercise preconditioning effects the expression and/or activity 
of MRP-1, thereby contributing to the exercise-induced extrusion of DOX from cardiac 
cells. 
5) In the current investigation, measurement of DOX accumulation was limited to 
the heart to determine a cardiotoxic relationship.  Exercise resulted in reduction of DOX 
accumulation and preservation of cardiac function.  However, DOX is known to cause 
toxicity in other tissues including kidney (Ray, Patel, Wong, & Bagchi, 2000), lung 
(Baciewicz, et al., 1991; Ray, et al., 2000) and liver (Mostafa, Mima, Ohnishi, & Mori, 
2000).  In future studies, it may be of interest to determine if exercise effects 
accumulation in other tissues including the liver, kidney, lung and skeletal muscle. 
6) Using HPLC, DOX accumulation was measured at 5 different time points over 
the course of 9 days in sedentary and exercise preconditioned rats.  However, 
pharmacokinetic parameters such as the area under the concentration-time curve, plasma 
clearance, distributive half-life, and volume of distribution were not included.  The 
aforementioned pharmacokinetic parameters can be used to describe the movement of 
DOX throughout the body (Ahmed, et al., 2009; Staples, et al., 2010; Urva, et al., 2009).  
Future study is needed to determine the effect of exercise on these parameters thus 
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Doppler mitral blood flow. 
Group Day N M-VTI (cm) M-Vmax (cm/s) M-Vmean (cm/s) 
SED+SAL 1 9 3.63 ± 0.12 91.85 ± 4.78 63.93 ± 2.94 
SED+DOX 1 10 3.51 ± 0.17 78.30 ± 1.99* 54.07 ± 2.94* 
 3 8 2.89 ± 0.21* 60.83 ± 4.37* 42.33 ± 3.24* 
 5 7 2.75 ± 0.16* 73.48 ± 8.62* 48.10 ± 5.49* 
 7 11 2.77 ± 0.20* 62.64 ± 4.68* 37.00 ± 4.36* 
 9 13 2.72 ± 0.13* 55.62 ± 2.90* 32.38 ± 2.63* 
TM+DOX 1 12 3.43 ± 0.11 85.69 ± 5.01 63.14 ± 3.88 
 3 13 3.89 ± 0.14 94.77 ± 4.04 64.82 ± 2.36 
 5 10 3.19 ± 0.22 93.23 ± 3.44 68.87 ± 3.46 
 7 10 3.25 ± 0.12* 87.17 ± 6.15 64.37 ± 4.66 
 9 6 3.29 ± 0.13* 100.11 ± 4.77 69.28 ± 3.03 
WR+DOX 1 10 3.59 ± 0.16 84.70 ± 4.66 64.47 ± 3.32 
 3 6 3.68 ± 0.18 96.00 ± 6.93 66.22 ± 4.21 
 5 10 3.29 ± 0.11* 92.77 ± 4.91 65.67 ± 3.17 
 7 8 3.38 ± 0.12 82.33 ± 4.37 59.54 ± 3.51 
 9 7 3.34 ± 0.16 84.90 ± 7.03 57.43 ± 5.96 
Values are M ± SEM 
SED+SAL, n = 9; SED+DOX, n = 49; TM+DOX, n = 51; WR+DOX, n = 
41 
M-VTI = Mitral velocity time integral 
M-Vmax = Mitral maximal flow velocity 
M-Vmean = Mitral mean flow velocity  













Doppler aortic blood flow. 
 
Group Day N A-VTI (cm) A-Vmax (cm/s) A-Vmean (cm/s) 
SED+SAL 1 9 2.90 ± 0.16 98.15 ± 2.95 56.07 ± 1.59 
SED+DOX 1 10 2.54 ± 0.17 80.47 ± 4.52* 47.33 ± 2.78* 
 3 8 2.10 ± 0.23* 67.71 ± 5.80* 42.00 ± 2.95* 
 5 6 2.74 ± 0.23 64.67 ± 4.57* 40.06 ± 2.07* 
 7 10 2.21 ± 0.19* 58.90 ± 4.15* 34.93 ± 2.23* 
 9 12 2.81 ± 0.32 62.33 ± 5.52* 36.78 ± 3.01* 
TM+DOX 1 12 2.50 ± 0.09* 84.11 ± 3.65 50.53 ± 2.08 
 3 13 3.24 ± 0.21 91.49 ± 5.46 57.44 ± 2.84 
 5 10 2.97 ± 0.14 103.50 ± 7.06 61.70 ± 3.74 
 7 10 3.20 ± 0.15 96.67 ± 5.19 60.00 ± 2.74 
 9 6 3.36 ± 0.26 93.56 ± 4.12 59.72 ± 2.68 
WR+DOX 1 10 2.63 ± 0.13 94.37 ± 3.96 56.07 ± 2.30 
 3 6 3.04 ± 0.26 86.39 ± 3.54 53.83 ± 2.49 
 5 10 3.28 ± 0.14 94.27 ± 3.14 57.00 ± 2.71 
 7 8 3.13 ± 0.28 83.29 ± 5.02 49.42 ± 2.79 
 9 6 3.21 ± 0.25 87.17 ± 6.48 54.00 ± 3.10 
Values are M ± SEM 
SED+SAL, n = 9; SED+DOX, n = 46; TM+DOX, n = 51; WR+DOX, n = 
40 
A-VTI = Aortic velocity time integral 
A-Vmax = Aortic maximal flow velocity 
A-Vmean = Aortic mean flow velocity 










Group Day N FS (%) 
SED+SAL 1 5 67.13 ± 3.11 
SED+DOX 1 11 56.50 ± 3.25* 
 3 6 52.39 ± 1.79* 
 5 5 56.48 ± 5.91* 
 7 8 50.95 ± 2.72* 
 9 8 50.47 ± 2.77* 
TM+DOX 1 13 65.01 ± 1.73 
 3 13 67.45 ± 2.69 
 5 9 59.43 ± 3.39 
 7 8 60.20 ± 3.86 
 9 4 61.60 ± 7.28 
WR+DOX 1 10 63.87 ± 3.03 
 3 9 62.25 ± 2.83 
 5 9 60.41 ± 2.46 
 7 7 58.49 ± 2.09 
 9 7 58.32 ± 4.33 
Values are M ± SEM 
SED+SAL, n = 5; SED+DOX, n = 38; TM+DOX, n = 47; WR+DOX, n = 
42 
FS = Fractional shortening 








Unpaced ex vivo cardiac function. 
Group Day N ESP EDP LVDP dP/dtmax dP/dtmin 
SED+SAL 1 9 97.99 ± 2.61 0.51 ± 0.76 97.48 ± 2.53 2851.24 ± 99.46 -2154.38 ± 60.62 
SED+DOX 1 13 101.76 ± 4.34 0.01 ± 0.48 101.74 ± 4.14 2894.12 ± 291.5 -2118.03 ± 331.6 
 3 12 91.75 ± 4.41 2.56 ± 0.45 89.18 ± 4.30 2723.99 ± 131.6 -2134.89 ± 161.8 
 5 11 85.85 ± 4.37* 1.25 ± 0.47 84.6 ± 4.65* 2567.01 ± 125.6* -1961.95 ± 82.03* 
 7 11 81.88 ± 6.66* 0.45 ± 0.82 81.43 ± 7.16* 2583.38 ± 245.7 -2077.90 ± 231.8 
 9 14 61.35 ± 2.95* 0.62 ± 0.44 60.73 ± 2.93* 1954.08 ± 66.98* -1523.75 ± 57.23* 
TM+DOX 1 13 110.52 ± 3.32* -1.55 ± 0.44* 112.06 ± 3.3* 3209.14 ± 82.37* -2565.22 ± 98.99* 
 3 12 103.56 ± 5.25 6.22 ± 0.49* 97.34 ± 4.83 2676.29 ± 100.6 -2115.69 ± 91.31 
 5 10 100.91 ± 5.94 2.58 ± 1.01 98.33 ± 6.05 2826.56 ± 181.6 -2262.07 ± 160.8 
 7 13 86.66 ± 3.15* 2.12 ± 0.60 84.54 ± 3.15* 2652.29 ± 120.0 -1942.06 ± 78.17* 
 9 10 88.21 ± 3.63* -0.40 ± 0.67 88.61 ± 3.98* 2517.73 ± 83.00* -1958.84 ± 55.03* 
WR+DOX 1 10 110.82 ± 3.49* 3.47 ± 0.47* 107.35 ± 3.46* 2799.00 ± 90.02 -2368.80 ± 65.85* 
 3 9 98.25 ± 3.01 1.75 ± 0.90 96.50 ± 3.46 2713.57 ± 146.8 -2089.58 ± 108.2 
 5 12 90.00 ± 4.26 0.81 ± 0.40 89.19 ± 4.19 2543.63 ± 110.9* -2017.32 ± 83.82 
 7 10 95.81 ± 4.90 -0.17 ± 0.37 95.98 ± 5.00 2882.18 ± 150.4 -2268.48 ± 131.9 
 9 10 81.45 ± 2.35* -0.87 ± 0.91 82.32 ± 1.69* 2376.79 ± 58.70* -1891.85 ± 64.20* 
Values are M ± SEM 
SED+SAL, n = 9; SED+DOX, n = 61; TM+DOX, n = 58; WR+DOX, n = 51 
ESP = End systolic pressure 
EDP = End diastolic pressure 
LVDP = Left ventricular developed pressure 
dP/dtmax = Maximal rate of pressure developed 
dP/dtmin = Maximal rate of pressure decline 












Paced ex vivo cardiac function. 
Group Day N ESP EDP LVDP dP/dtmax dP/dtmin 
SED+SAL 1 9 112.13 ± 3.15 1.75 ± 0.85 110.38 ± 2.81 3450.68 ± 101.1 -2574.30 ± 118.2 
SED+DOX 1 13 98.74 ± 3.15*  1.21 ± 0.57 97.52 ± 3.24* 3033.15 ± 276.1 -2264.74 ± 140.6 
 3 12 94.49 ± 3.86* 3.08 ± 0.42 91.42 ± 3.93* 2952.32 ± 101.4* -2292.44 ± 155.4 
 5 11 82.18 ± 3.32* 1.76 ± 0.33 80.42 ± 3.44* 2691.47 ± 74.36* -2021.69 ± 69.69* 
 7 11 85.91 ± 5.60* 1.45 ± 0.77 84.46 ± 5.97* 2861.01 ± 176.5* -2066.68 ± 130.5* 
 9 14 71.49 ± 3.37* 1.03 ± 0.57 70.46 ± 3.28* 2401.42 ± 99.03* -1803.16 ± 85.10* 
TM+DOX 1 13 109.04 ± 1.91 -0.89 ± 0.47* 109.93 ± 1.87 3402.00 ± 78.50 -2751.75 ± 87.07 
 3 12 106.18 ± 4.52 6.49 ± 0.66* 99.69 ± 4.17* 2960.59 ± 111.7* -2202.45 ± 85.87* 
 5 10 105.84 ± 5.79 2.88 ± 0.96 102.96 ± 5.98 3298.98 ± 300.9 -2405.33 ± 165.5 
 7 13 92.17 ± 5.05* 2.59 ± 0.62 89.58 ± 5.00* 3009.52 ± 160.8* -2233.95 ± 160.7 
 9 10 94.20 ± 3.42* 0.37 ± 0.67 93.83 ± 3.76* 2997.16 ± 121.1* -2139.66 ± 64.65* 
WR+DOX 1 10 111.56 ± 3.75 4.28 ± 0.52* 107.28 ± 3.72 3279.88 ± 108.9 -2566.07 ± 114.6 
 3 9 96.34 ± 1.37* 2.05 ± 0.72 94.29 ± 1.54* 2935.78 ± 95.73* -2270.70 ± 71.68* 
 5 12 99.47 ± 4.74* 1.25 ± 0.31 98.23 ± 4.64* 3029.98 ± 160.2* -2357.55 ± 148.0 
 7 10 104.24 ± 4.74* -0.11 ± 0.28 104.34 ± 4.66 3343.82 ± 164.1 -2616.42 ± 149.5 
 9 10 90.60 ± 2.34* 0.99 ± 0.90 89.61 ± 2.47* 2993.21 ± 149.9* -2068.54 ± 80.99* 
Values are M ± SEM 
SED+SAL, n = 9; SED+DOX, n = 61; TM+DOX, n = 58; WR+DOX, n = 51 
ESP = End systolic pressure 
EDP = End diastolic pressure 
LVDP = Left ventricular developed pressure 
dP/dtmax = Maximal rate of pressure developed 
dP/dtmin = Maximal rate of pressure decline 












Left ventricular DOX accumulation.  
Day SED+DOX 
(ng DOX/g LV) 
TM+DOX 
(ng DOX/g LV) 
WR+DOX 
(ng DOX/g LV) 
1 702.16 ± 24.90* 416.88 ± 42.89 a 525.68 ± 30.61a 
3 484.49 ± 36.14* 219.64 ± 21.61a 173.25 ± 11.57 a 
5 178.15 ± 21.09* 83.94 ± 17.19 a 54.67 ± 7.82 a 
7 97.37 ± 24.59* N/D a N/D a 
9 N/D N/D N/D 
Values are M ± SEM 
SED+DOX, n = 65; TM+DOX, n = 61; WR+DOX, n = 61 
N/D = Not detectable 
* Significant difference between groups (p < 0.001) 
a Significantly less than SED+DOX (p < 0.05) 
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